ZA200505934B - Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors - Google Patents
Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors Download PDFInfo
- Publication number
- ZA200505934B ZA200505934B ZA200505934A ZA200505934A ZA200505934B ZA 200505934 B ZA200505934 B ZA 200505934B ZA 200505934 A ZA200505934 A ZA 200505934A ZA 200505934 A ZA200505934 A ZA 200505934A ZA 200505934 B ZA200505934 B ZA 200505934B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- product
- alkyl
- radicals
- optionally substituted
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 10
- 229940043355 kinase inhibitor Drugs 0.000 title claims 2
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical class OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- -1 heterocyclic radical Chemical class 0.000 claims description 332
- 125000000217 alkyl group Chemical group 0.000 claims description 192
- 229910052739 hydrogen Inorganic materials 0.000 claims description 135
- 239000001257 hydrogen Substances 0.000 claims description 135
- 150000003254 radicals Chemical class 0.000 claims description 127
- 229910052760 oxygen Inorganic materials 0.000 claims description 85
- 150000002431 hydrogen Chemical class 0.000 claims description 69
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 62
- 239000011707 mineral Substances 0.000 claims description 62
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 59
- 125000004432 carbon atom Chemical group C* 0.000 claims description 58
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 56
- 125000003118 aryl group Chemical group 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 56
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 52
- 239000001301 oxygen Substances 0.000 claims description 52
- 125000001424 substituent group Chemical group 0.000 claims description 52
- 125000003545 alkoxy group Chemical group 0.000 claims description 49
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 48
- 125000001072 heteroaryl group Chemical group 0.000 claims description 47
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 46
- 229910052757 nitrogen Inorganic materials 0.000 claims description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 229910052717 sulfur Inorganic materials 0.000 claims description 34
- 125000003342 alkenyl group Chemical group 0.000 claims description 33
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 32
- 150000007522 mineralic acids Chemical class 0.000 claims description 31
- 150000007524 organic acids Chemical class 0.000 claims description 31
- 235000005985 organic acids Nutrition 0.000 claims description 31
- 150000007530 organic bases Chemical class 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 102000001253 Protein Kinase Human genes 0.000 claims description 21
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- 108060006633 protein kinase Proteins 0.000 claims description 21
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 125000002837 carbocyclic group Chemical group 0.000 claims description 13
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 12
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 238000002512 chemotherapy Methods 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 claims description 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 31
- 239000000126 substance Substances 0.000 claims 29
- 238000000034 method Methods 0.000 claims 20
- 229940126601 medicinal product Drugs 0.000 claims 19
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 17
- 150000001721 carbon Chemical group 0.000 claims 15
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 12
- 125000004193 piperazinyl group Chemical group 0.000 claims 12
- 125000002757 morpholinyl group Chemical group 0.000 claims 11
- 125000005936 piperidyl group Chemical group 0.000 claims 11
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 7
- 229940080818 propionamide Drugs 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 125000002883 imidazolyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 125000000335 thiazolyl group Chemical group 0.000 claims 5
- WUEPMEXUMQVEGN-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;2,2,2-trifluoro-n-[2-[2-[(2,2,2-trifluoroacetyl)amino]ethylamino]ethyl]acetamide Chemical compound OC(=O)C(F)(F)F.FC(F)(F)C(=O)NCCNCCNC(=O)C(F)(F)F WUEPMEXUMQVEGN-UHFFFAOYSA-N 0.000 claims 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 4
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000005493 quinolyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 3
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical compound [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 claims 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000003838 furazanyl group Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000003725 azepanyl group Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 230000003831 deregulation Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 210000004324 lymphatic system Anatomy 0.000 claims 2
- 210000003584 mesangial cell Anatomy 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000001625 seminal vesicle Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 201000010653 vesiculitis Diseases 0.000 claims 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- DEIYDPRULONZAB-UHFFFAOYSA-N 5-[[4-[[5,5-dimethyl-2,4-dioxo-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidin-1-yl]methyl]pyridin-2-yl]amino]pyridine-2-carboxylic acid Chemical compound O=C1N(C=2C=CC(SC(F)(F)F)=CC=2)C(=O)C(C)(C)N1CC(C=1)=CC=NC=1NC1=CC=C(C(O)=O)N=C1 DEIYDPRULONZAB-UHFFFAOYSA-N 0.000 claims 1
- 101100329003 Arabidopsis thaliana COV1 gene Proteins 0.000 claims 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 101100342473 Drosophila melanogaster Raf gene Proteins 0.000 claims 1
- 101150017750 FGFRL1 gene Proteins 0.000 claims 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 102100026149 Fibroblast growth factor receptor-like 1 Human genes 0.000 claims 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 1
- 101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 101100523549 Xenopus laevis raf1 gene Proteins 0.000 claims 1
- 101150037250 Zhx2 gene Proteins 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims 1
- 229940047889 isobutyramide Drugs 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 26
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 24
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 24
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000035578 autophosphorylation Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 2
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108091006082 receptor inhibitors Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 108091009389 Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
- 102000018546 Paxillin Human genes 0.000 description 1
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000005853 oncogenic activation Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009396 radiation induced apoptosis Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
®
The present invention also relates to novel FAK receptor inhibitors that may be used for oncology treatments.
The present invention also relates to novel AKT receptor inhibitors that may be used for oncology treatments. :
Cancer remains a disease for which the existing treatments are clearly insufficient. Certain protein kinases, especially including IGF-1R (Insulin Growth
Factor 1 Receptor), play an important role in many cancers. The inhibition of such protein kinases is potentially important in the chemotherapy of cancers, especially for suppressing the growth or survival of tumors. The present invention thus relates to the E identification of novel products that inhibit such protein kinases. :
Protein kinases participate in signaling events that : control the activation, growth and differentiation of ‘ cells in response either to extracellular mediators or to changes in the environment. In general, these kinases oo belong to two groups: those that preferentially phosphorylate serine and/or threonine residues and those that preferentially phosphorylate tyrosine residues (S.K. Hanks and T. Hunter, FASEB. J., 1995, 9, pages 576- 596]. The serine/threonine kinases are, for example, the isoforms of the protein kinases C [A.C. Newton, J. Biol.
Chem., 1995, 270, pages 28495-28498] and a group of cycline-dependent kinases, for instance cdc2 [J. Pines,
Trends in Biochemical Sciences, 1995, 18, pages 195-197).
Tyrosine kinases comprise growth factor receptors, for instance the epidermal growth factor (EGF) receptor [S. Iwashita and M. Kobayashi, Cellular Signalling, 1992, 4, pages 123-132], and cytosol kinases, for instance pS6tck, p59f¥Yn and ZAP-70 and the kinases csk [C. Chan et. al., Ann. Rev. Immunol., 1994, 12, pages 555-592].
® : . Abnormally high levels of kinase protein activity : have been implicated in many diseases, resulting from abnormal cellular functions. This may arise either directly or indirectly from a dysfunction in the mechanisms for controlling the kinase activity, linked, for example, to a mutation, an overexpression or an inappropriate activation of the enzyme, or an over- or underproduction of cytokines or of growth factors, also involved in the transduction of the signals upstream or downstream of the kinases. In all these cases, a selective inhibition of the action of the kinases offers hope of a beneficial effect.
The type 1 receptor for in the insulin-like growth factor (IGF-I-R) is a transmembrane receptor with tyrosine kinase activity which binds firstly to IGFI, but also to IGFII and to insulin with lower affinity. The binding of IGF1 to its receptor results in oligomerization of the receptor, the activation of tyrosine kinase, intermolecular autophosphorylation and the phosphorylation of cell substrates (main substrates:
IRS1 and Shc). The receptor activated by its ligand induces mitogenic activity in normal cells. However,
IGF-I-R plays an important role in “abnormal” growth.
Several «clinical reports underline the important role of the: IGF-I route in the development of human: cancers:
IGF-I-R is often found overexpressed in many types of tumor (breast, colon, lung, sarcoma, etc.) and its presence 1s often associated with a more aggressive phenotype.
High concentrations of circulating IGF1l are strongly correlated with a risk of prostate cancer, lung cancer and breast cancer.
Furthermore, it has been widely documented that
IGF-I-R is necessary for establishing and maintaining the transformed phenotype in vitro as in vivo [Baserga R,
eo
Exp. Cell. Res., 1999, 253, pages 1-6]. The kinase activity of IGF-I-R is essential for the transformation activity of several oncogenes: EGFR, PDGFR, the large T antigen of the SV40 virus, activated Ras, Raf, and v-Src.
The expression of IGF-I-R in normal fibroblasts induces a neoplastic phenotype, which may then result in the formation of a tumor in vivo. The expression of IGF-I-R plays an important role in substrate-independent growth.
IGF-I-R has also been shown to be a protector in chemotherapy-induced and radiation-induced apoptosis, and cytokine-induced apoptosis. Furthermore, the inhibition of endogenous IGF-I-R with a negative dominant, the formation of a triple helix or the expression of an antisense sequence brings about suppression of the R transforming activity in vitro and reduction of tumor growth in animal models.
Among the kinases for which a modulation of the : activity is desired, FAK (Focal Adhesion Kinase) is also : a preferred kinase.
FAK is a cytoplasmic tyrosine kinase that plays an on important role in tranducing the signal transmitted by the integrins, a family of heterodimeric receptors of cellular adhesion. FAK and the integrins are colocalized in perimembrane structures known as adhesion plaques. It has been shown in many cell types that the activation of
FAK and its phosphorylation on tyrosine residues and in particular its autophosphorylation on tyrosine 397 were dependent on the binding of the integrins to their extracellular ligands and thus induced during cellular adhesion [Kornberg L, and al. J. Biol. Chem. 267(33): 23439-442 (1992)]. The autophosphorylation on tyrosine 397 of FAK represents a binding site for another tyrosine kinase, Src, via its SH2 domain [Schaller et al. Mol.
Cell. Biol. 14 : 1680-1688 1994 ; Xing et al. Mol. Cell.
Biol. 5 : 413-421 1994]. Src can then phosphorylate FAK on tyrosine 925, thus recruiting the adapter protein Grb2 o 5 and. inducing in: certain cells activation of the ras and
MAP kinase pathway involved in controlling cellular proliferation [Schlaepfer et al. Nature ; 372 : 786-791 1994; Schlaepfer et al. Prog. Biophy. Mol. Biol. 71: 435- 478 1999 ; Schlaepfer and Hunter, J. Biol. Chem. 272: 13189-13195 1997].
The activation of FAK can thus induce the jun NH2- terminal kinase (JNK) signaling pathway and result in the progression of the cells to the Gl phase of the cellular cycle [Oktay et al., J. Cell. Biol.145: 1461-1469 1999].
Phosphatidylinositol-3-OH kinase (PI3-kinase) also binds to FAK on tyrosine 397 and this interaction might be necessary for the activation of PI3-kinase [Chen and
Guan, Proc. Nat. Acad. Sci. USA. 91: 10148-10152 1994;
Ling et al. J. Cell. Biochem. 73: 533-544 1999]. The
FAK/Src complex phosphorylates various substrates, for instance paxillin and pl30CAS in fibroblasts ([Vuori et al. Mol. Cell. Biol. 16: 2606-2613 1996].
The results of numerous studies support the hypothesis that FAK inhibitors might be useful in treating cancer. Studies have suggested that FAK might play an important role in in vitro cell proliferation and/or survival. For example, in CHO cells, certain authors have demonstrated that the overexpression of pl25FAK induces an acceleration of the Gl to § transition, suggesting that pl25FAK promotes cellular proliferation (Zhao J.-H et al. J. Cell Biol. 143: 1997- 2008 139%8]. Other authors have shown that tumor cells treated with FAK antisense oligonucleotides lose their adhesion and go into apoptosis (Xu et al, Cell Growth
Differ. 4: 413-418 1996). It has also been demonstrated that FAK promotes the migration of cells in vitro. Thus, fibroblasts that are deficient for the expression of FAK (“knockout” mice for FAK) show a rounded morphology and deficiencies in cell migration in response to chimiotactic signals, and these defects are suppressed by
® reexpression of FAK [DJ. Sieg et al., J. Cell Science. 112: 2677-91 1999]. The overexpression of the C-terminal domain of FAK (FRNK) blocks the stretching of adherent cells and reduces cellular migration in vitro [Richardson
A. and Parsons J.T. Nature. 380: 538-540 1996]. The overexpression of FAK in CHO or COS cells or in human astrocytoma cells promotes migration of the cells. The involvement of FAK in promoting the proliferation and migration of cells in numerous cell types in vitro suggests the potential role of FAK in neoplastic processes. A recent study has effectively demonstrated the increase in the proliferation of tumor cells in vivo after induction of the expression of FAK in human astrocytoma cells [Cary L.A. et al. J. Cell Sci. 109: 1787-94 1996; Wang D et al. J. Cell Sci. 113: 4221-4230 2000]. Furthermore, immunochistochemical studies on human biopsies have demonstrated that FAK is overexpressed in : prostate cancer, breast cancer, thyroid cancer, cancer of the colon, melanoma, brain cancer and lung cancer, the level of expression of FAK being directly correlated to we the tumors having the most aggressive phenotype [Weiner
TM, et al. Lancet. 342 (8878): 1024-1025 1993; Owens et al. Cancer Research. 55: 2752-2755 1995; Maung K. et al.
Oncogene 18: 6824-6828 1999; Wang D et al. J. Cell Sci. 113: 4221-4230 2000].
Protein kinase AKT (also known as PKB) and phosphoinositide 3-kinase (PI3K) are involved in a cell signaling pathway that transmits signals from growth factors activating membrane receptors.
This transduction pathway is involved in numerous cellular functions: regulation of apoptosis, control of transcription and translation, glucose metabolism, angiogenesis and mitochondrial integrity. First identified as an important component of insulin-dependent signaling pathways regulating metabolic responses, serine/threonine kinase AKT was then identified as a
® 7 : mediator playing a key role in survival induced with growth factors. It has been shown that AKT can inhibit death by apoptosis induced by various stimuli, in a certain number of cell types and tumor cells. In accordance with these findings, it has been shown that
AKT can, by phosphorylation of given serine residues, inactivate BAD, GSK3f, caspase-9, and Forkhead transcription factor, and can activate IKKalpha and e-NOS. It is interesting to note that the protein BAD is found hyper-phosphorylated in 11 human tumor cell lines out of 41 studied. Furthermore, it has been shown that hypoxia modulates the induction of VEGF in cells transformed with Ha-ras by activating the PI3K/AKT pathway and by involving the binding sequence of the
HIF-1 (hypoxia inducible factor-1) transcription factor known as HRE for “hypoxy-responsive element”.
AKT plays a very important role in cancer pathologies. The amplification and/or overexpression of
AKT has been reported in many human tumors, for instance gastric carcinoma (amplification of AKT1), ovary carcinoma, breast carcinoma or pancreatic carcinoma (amplification and overexpression of AKT2) and breast carcinomas deficient in estrogen receptors, and also androgen-independent prostate carcinomas (overexpression of AKT3). Furthermore, AKT is constitutively activated in all the PTEN (-/-) tumors, the PTEN phosphatase being deleted or inactivated by mutations in many types of tumors, for instance carcinomas of the ovary, of the prostate, of the endometrium, gliocblastomas and melanomas. AKT is also involved in the oncogenic activation of bcr-abl (references: Khawaja A., Nature 1999, 401, 33-34; Cardone et al. Nature 1998, 282, 1318- 1321; Kitada S. et al., Am J Pathol 1998 Jan; 152(1): 51- 61; Mazure NM et al. Blood 1997, 90, 3322-3331; Zhong H. et al. Cancer Res. 2000, 60, 1541-1545).
: One subject of the present invention is thus the products of general formula (I): : . 5 )
R1 vy
R3 A— ! pal
N Y, " A
A oo 2 v0) §
Y, "10 in which p represents an integer from 0 to 2,
R and Rl, which may be identical or different, represent
O or NH,
R2 and R3, which may be identical or different, represent : hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3- to 10- membered and the heterocyclic radical containing one or more hetero atoms chosen from O, S, N and NR7, all these radicals optionally being substituted,
Al represents a single bond, an alkyl radical or an allyl or propynyl radical,
® 9
Y and Yl, which may be identical or different, are such that one from among Y and Y1 is chosen from OCF3, -0O-CF2-
CHF2, -0O-CHF2, -0-CH2-CF3, SO2NR5R6, SF5 and -S(0)n-alkyl and the other from among Y and Y1 is chosen from these same values and in addition from the following values: hydrogen, halogen, hydroxyl, alkoxy, nitro, CN, NRSR6, optionally substituted alkyl, optionally substituted aryl and heteroaryl, CF3, O-alkenyl, O-alkynyl, O-cycloalkyl,
S(O)n-alkenyl, S(O)n-alkynyl, S(O)n-cycloalkyl, free, salified or esterified carboxyl and CONRSRE, or alternatively the phenyl radical forms with its substituents ¥ and Y1 the following radicals:
Ae Lo with p representing the integer 2, 3 or 4, the radical thus formed being optionally substituted with one or more alkyl radicals that are themselves optionally substituted,
R5 and Ré6, which may be identical or different, are chosen from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, ‘cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which are optionally substituted, or alternatively R5 and Ré6 form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, which is optionally substituted,
A2, which may be identical to or different from Al, represents the values of Al and CO and S02,
B2 represents a saturated or unsaturated monocyclic or bicyclic heterocyclic radical «containing 1 or more identical or different hetero atoms chosen from 0, S, N and NR7, optionally substituted with one or more
® | 10 : identical or different substitutents chosen from the values of Y2,
R7 represents a hydrogen atom or an alkyl, cycloalkyl, phenyl, acyl, S(0)2Alk, S(0O)2Aryl, S(O)2hetercaryl or
S(0)2NRSR6 radical,
Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aryl, heteroaryl, -0O-alkenyl, -0O-alkynyl, -O-cycloalkyl, -S(0)n-alkyl, -S(0)n-alkenyl, -S(0)n-alkynyl,
S(O)n-cycloalkyl, COOR13, -OCOR13, NRSR6, CONRSRS,
S (O)n-NR5R6, -NR10-CO-R13, -NR10-S02-R13, NH-SO2-NRG5R6, -NR10-CO-NRSR6, -NR10-CS-NR5R6, -NR10-COOR13, all these radicals optionally being substituted, all the alkyl, alkenyl, alkynyl and alkoxy radicals above R being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl and heterocycloalkyl radicals above containing not more than 7 carbon atoms, ‘ all the aryl and heteroaryl radicals above containing not more than 10 carbon atoms, = all the «carbocyclic and heterocyclic alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and hetercaryl radicals above, and also the ring formed by R5 and R6 with the atom to which they are attached, optionally being substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, aryl, heteroaryl, -C(=0) -0OR9, -C(=0) -R8, -NR11R1l2, -C(=0) -
NR11R12, -N (R10) -C(=0) -R8, -N(R10)-C(=0)-OR9, N(R10)-C(=0)-NR11R12, -N(R10)-S(O)n-
R8, -S(0O)n-RS8, -N(R10)-S{0)n-NR11R12 or -S(0O)n-NR11R12 radicals, all the aryl and heteroaryl radicals above furthermore being optionally substituted with one or more radicals chosen from alkyl, alkoxy and alkylenedioxy radicals,
® 11 all the cyclic radicals above, and also the ring formed : by R5 and R6 with the atom to which they are attached, being moreover optionally substituted with one or more radicals chosen from oxo and thioxo, n represents an integer from 0 to 2,
R8 represents alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heterocarylalkyl,
RS represents the values of R8 and hydrogen,
R10 represents hydrogen or alkyl,
R11 and R12, which may be identical or different, represent hydrogen, C3-Cé6 cycloalkyl, Cl-C4 alkyl and phenyl, optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively R11 and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from
O, S, N and NR7 and preferably a cyclic amine,
R13, which may be identical to or different than RS or
R6, being chosen from the values of RS5 or R6, it being understood that the products of formula (I) are as defined below from a) to 4d): a) when p represents the integer 0, R represents oxygen,
R1 represents oxygen, Al represents a single bond or alkyl, Y¥ and Yl, which may be identical or different, are such that at least one represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and
R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yi, which may be identical or different, are such that at least one represents OCF3, SOAlk, S{(0)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain : optionally interrupted with O, 8 or Nalk, always
S substituted with a hydroxamate -CO-NHCH c) when p represents the integer 0, R and Rl. represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents S{(O)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6- membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Y1, which may be identical or different, are such that one represents SO2Alk or SO2NH2 and the other represents : NRSR6, A2 represents a single bond or alkylene and B2 : represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both ws represent hydrogen, said products of formula (I) being in any possible racemic, enantiomeric or diasterecisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I).
A subject of the present invention is thus the products of general formula (I) as defined above in which p represents an integer from 0 to 2,
R and R1l, which may be identical or different, represent
O or NH,
R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or
® 13 heterocyclic radical, these radicals being 3- to 10- : membered and the heterocyclic radical containing one or more hetero atoms chosen from CO, S, N and NR7, all these radicals optionally being substituted,
Al represents a single bond, an alkyl radical or an allyl or propynyl radical,
Y and Yl, which may be identical or different, are such that one from among Y and Y1 is chosen from OCF3,
S(O)nCF3, S(0)nAlk, SO2CHF2, SO2CF2CF3 and SO02NR5R6 and the other from among Y and Y1 is chosen from these same values and in addition from. the following values: hydrogen, halogen, hydroxyl, alkoxy, NR5R6, optionally substituted alkyl, optionally substituted aryl and heteroaryl, CF3, O-allyl, O-propynyl, O-cycloalkyl,
S(O)n-allyl, S(0O)n-propynyl, S(0O)n-cycloalkyl, free, salified or esterified carboxyl and CONRS5R6 in which R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocyclecalkyl, aryl and heteroaryl, which are optionally substituted, or alternatively R5 and
R6 form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from O, S, N and NR7, which is optionally substituted,
A2, which may be identical to or different from A1, represents the values of Al and CO and S02,
B2 represents a saturated or unsaturated heterocyclic radical containing 1 or more identical or different hetero atoms chosen from O, S, N and NR7, optionally substituted with one or more identical or different substitutents chosen from the values of Y2,
R7 represents a hydrogen atom or an alkyl, cycloalkyl, phenyl, aryl, S(0)2alk, S(0O)2aryl, S(0)2heterocaryl or
S (QO) 2NRSR6 radical,
Y2 represents hydrogen, halogen, hydroxyl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, O-allyl,
hd 14 : O-propynyl, O-cycloalkyl, S(0)n-alkyl, S(0)n-allyl,
S(O)n-propynyl, S(O)n-cycloalkyl, COORS, OCOR8, NRSR6,
CONR5R6, S(0O)n-R5R6, NHCOR8, NH-S(0O)nR8 or NH-S (0) nCF3 or :
NH-SO2-NR5R6, all these radicals being optionally substituted, all the alkyl, alkenyl, alkynyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl and heterocycloalkyl radicals above containing not more than 7 carbon atoms, all the aryl and heteroaryl radicals above containing not more than 10 carbon atoms, all the carbocyclic and heterocyclic alkyl, alkenyl, : alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and R heteroaryl radicals above optionally being substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, : alkoxy, CF3, nitro, aryl, heteroaryl, -C(=0) -0R9, -C(=0)-R8, -NR11R12, -C(=0)-NR11R12, -N(R10)-C(=0)-RS8, -N(R10)-C(=0)-0R9, N(R10)-C(=0) -NR11R12, -N (R10) -S(0O)n- ne R8, -S(0O)n-RS8, -N(R10)-S(0O)n-NR11R12 or -S(0)n-NR11R12 radicals, all the aryl and heteroaryl radicals above furthermore being optionally substituted with one or more radicals chosen from alkyl and alkylenedioxy radicals, n represents an integer from 0 to 2,
R8 represents alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heterocarylalkyl,
R9 represents the values of R8 and hydrogen,
R10 represents hydrogen or alkyl,
R11 and R12, which may be identical or different, represent hydrogen, C3-C6 cycloalkyl, Cl1-C4 alkyl and phenyl, optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms
® 15 : and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively R11 and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from 0, 8S, N and NR7 and preferably a cyclic amine, it being understood that the products of formula (I) are as defined below from a) to d): a) when p represents the integer 0, R represents oxygen,
R1 represents oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that at least one represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and
R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that at least one represents OCF3, SOAlk, S(0)2alk or SO0O2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk always substituted with a hydroxamate -CO-NHOH : c) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that at least one represents S(O)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6- membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and R1 represent oxygen, Al represents a single bond, Y and Yi, which may be identical or different, are such that one
® 16 : represents SO2Alk or SO2NH2 and the other represents
NRESR6, AZ2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered : heterocyclic radical, then R2 and R3 do not both represent hydrogen, | : said products of formula (I) being in any possible racemic, enantiomeric or diasterecisomeric isomer: form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I).
One subject of the present invention is thus the products of general formula (I) as defined above in which p represents an integer from 0 to 2, | :
R and R1l, which may be identical or different, represent E
O or NH,
R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, cycloalkyl, phenyl and heteroaryl, which are optionally substituted, or ‘ alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or - heterocyclic radical, these radicals being from 3- to 10-membered and the heterocyclic radical containing one or more hetero atoms chosen from 0, 8S, N and NR7, all these radicals being optionally substituted,
Al represents a single bond, an alkyl radical or an allyl or propynyl radical,
Y and Y1, which may be identical or different, are such that one from among Y and Y1 is chosen from OCF3,
S(0)nCF3, S(0)nAlk, SO2CHF2, SO2CF2CF3 and SO2NR5R6 and the other from among Y and Yl is chosen from these same values and in addition from the following values: hydrogen, halogen, hydroxyl, alkoxy, NR5R6, optionally substituted alkyl and phenyl, and optionally substituted pyrazolyl and pyridyl, with RS5 and Ré6, which may be identical or different, chosen from hydrogen, alkyl, alkenyl, cycloalkyl,
® 17 heterocycloalkyl, phenyl and heteroaryl, which are : optionally substituted, or alternatively RS5 and Ré form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7, which are optionally substituted,
A2, which may be identical to or different than Al, represents the values of Al and CO and S02,
B2 represents a saturated or unsaturated heterocyclic radical containing one or more identical or different hetero atoms chosen from O, S, N and NR7, optionally substituted with one or more identical or different substituents chosen from the values of Y2, :
R7 represents a hydrogen atom or an alkyl, cycloalkyl or phenyl radical,
Y2 represents hydrogen, halogen, hydroxyl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, phenyl, heteroaryl,
O-cycloalkyl, S(O)n-alk, S(0O)n-cycloalkyl, COORS, OCORS,
NR5R6, CONRSR6, S{0O)n-R5R6, NHCOR8 and NH-S(0O)nR8, all these radicals being optionally substituted, all the above alkyl, alkenyl, alkynyl and alkoxy radicals being linear or branched and containing up to 6 carbon atoms, all the above cycloalkyl and heterocycloalkyl radicals containing up to 7 carbon atoms, all the above aryl and heteroaryl radicals containing up to 10 carbon atoms, all the above alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, carbocyclic and heterocyclic radicals being optionally substituted with one or more identical or different radicals chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl, heteroaryl, -C(=0) -ORg9, -C(=0)-R8, -NR11lR12, -C(=0)-NR11R12, -N(R10)-C(=0)-Rs, -N{(R1l0)-C(=0) -0OR9, N (R10) -C(=0) -NR11R12, -N(R10) -
hd 18
S(0)n-R8, -S(0)n-R8, -N(R10)-S(0)n-NR11R12 and -S(0)n- ~ NR11R12, all the aryl and heteroaryl radicals above moreover being optionally substituted with one or more radicals chosen from alkyl and alkylenedioxy radicals, n represents an integer from 0 to 2, :
R8 represents alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, phenyl and phenylalkyl,
RS represents the values of R8 and hydrogen,
R10 represents hydrogen or alkyl,
R11 and R12, which may be identical or different, represent hydrogen, C1-C4 alkyl and phenyl, optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively R11 and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more ans hetero atoms chosen from O, S, N and NR7 and preferably a cyclic amine, it being understood that the products of formula (I) are as defined below from a) to 4d): a) when ©p represents the integer 0, R represents
Oxygen, Rl represents Oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that at least one represents OCF3 or Salk, a2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and
R3 do not represent a hydrogen for one and imidazolylalkyl for the other, b) when p represents the integer 0, R and R1 represent
Oxygen, Al represents a single bond or alkyl, Y and Yi, which may be identical or different, are such that at least one represents OCF3, SOAlk, S(0C)2alk or SO2NH2, a2
® 19 represents CH2 and B2 represents an optionally : substituted heterocyclic radical, then R2 and R3 do not represent a hydrogen atom for one and, for the other, an alkyl chain optionally interrupted with O, S, Nalk always substituted with a hydroxamate -CO-NHOH, c) when p represents the integer 0, R and Rl represent
Oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that at least one represents S(O)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Y1, which may be identical or different, are such that one represents SO02Alk or SO2NH2 and the other represents
NRSR6, A2 represents a single bond or alkylene and R2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I).
One subject of the present invention is thus the products of formula (I) as defined above in which Y and Y1, which may be identical or different, are such that one from among Y and Yl is chosen from OCF3, -O-CF2-CHF2, -O-CHF2, -0-CH2-CF3, S(O)nCF3, -S-CF2-CF2-CF3, -S(0)n-Alk, -S-Alk-0-Alk, -S-Alk-OH, ~-S-Alk-CN, -S-Alk- heterocycloalkyl, -SO2CHF2, -S02CF2CF3, -SO2NR5R6 and -SF5, with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, and the other from among Y and
® 20 : Yl is chosen from the following values: hydrogen, halogen, nitro, NR5R6, free or esterified carboxyl and
CONRSRE, or alternatively the phenyl radical forms with its substituents Y and Yl one of the following radicals:
A 3 oo (ONNe . © 5 the radical thus formed being optionally substituted with one or more alkyl radicals that are themselves optionally substituted, oo "the other substituents on said products of formula (I) B being chosen from the values defined in claim 1 and it being understood that: : a) when p represents the integer 0, R represents oxygen, Rl represents Oxygen, Al represents a single bond ' or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other we represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent hydrogen for one and imidazolylalkyl for the other, b) when p represents the integer 0, R and Rl represent
Oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that one represents hydrogen and the other represents OCF3, SOAlk,
S(0)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent hydrogen for one and, for the other, an alkyl chain optionally interrupted with O, g,
Nalk always substituted with a hydroxamate-CO-NHOH, c) when p represents the integer 0, R and R1 represent
Oxygen, Al represents a single bond or alkyl, Y and Yi, which may be identical or different, are such that one
® 21 represents hydrogen and the other represents S(0O)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I).
A subject of the present. invention is thus the products of general formula (I) as defined above in which one from among Y and Yl represents a hydrogen atom and the other is chosen from OCF3, S(0)nCF3, S(0)nalk,
SO2CHF2, SO2CF2CF3 and SO2NR5R6, the other substituents of said products of formula (I) being chosen from the values defined above, it being understood that: a) when p represents the integer 0, R represents oxygen,
R1 represents oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that one represents hydrogen and the other represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yi, which may be identical or different, are such that one represents hydrogen and the other represents OCF3, SOAlk,
S(0)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk always substituted with a hydroxamate -CO-NHOH
® 22 c) when p represents the integer 0, R and R1 represent oxygen, Al represents a single bond or alkyl, ¥ and Y1, which may be identical or different, are such that one : represents hydrogen and the other represents S(O)nAlk, AZ represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said products of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). | :
A subject of the present invention is thus the products of general formula (I) as defined above in which one from among Y and Y1 represents a hydrogen atom and the other is chosen from S(0)nCF3, S80Alk, S(0)2alk, : SO2CHF2, SO2CF2CF3 and SO2NRG5R6, ' the other substituents of said products of formula (I) being chosen from the values defined above and it being = understood that the products of formula (I) are as defined below in a) and b): a) when p represents the integer 0, R and R1l represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that one represents hydrogen and the other represents SOAlk,
S(0)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk always substituted with a hydroxamate -CO-NHOH b) when p represents the integer 0, R and R1 represent oxygen, Al represents a single bond or alkyl, Y and vi, which may be identical or different, are such that one represents hydrogen and the other represents SOAlk or
S(0)2Blk, A2 represents a single bond and B2 represents
. ® 23 . an optionally substituted 5- or 6-membered aromatic : heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said products of formula (I) being in any possible racemic, enantiomeric or diastereocisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I).
A subject of the present invention is thus the products of general formula (I) as defined above in which one from among Y and Y1 represents a hydrogen atom and the other is chosen from S(0)nCF3, SO2CHF2, SO2CF2CF3 and
SO2NRSR6, the other substituents of said products of formula (I) being chosen from the values defined above and it being understood that when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that one represents hydrogen and the other represents
SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted by O, S or Nalk, always substituted with a hydroxamate -CO-NHOH said products of formula (I) being in any possible racemic, enantiomeric and diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I).
In the products of formula (I) and subsequently, the terms indicated have the following meanings: - the term “Hal”, “Halo” or halogen denotes fluorine, chlorine, bromine or iodine atoms, - the term “alkyl”, “alk”, "“Alk” or “ALK” denotes a linear or branched radical containing not more than 12 carbon atoms, chosen from methyl, ethyl, propyl,
hd 24 : isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, sec-pentyl, tert-pentyl, neopentyl, hexyl, isohexyl, sec-hexyl, tert-hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl radicals, and .also the linear or branched positional isomers thereof.
Mention is made more particularly of alkyl radicals containing not more than 6 carbon atoms, and especially methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, linear or branched pentyl and linear or branched hexyl radicals. - the term “alkenyl radical” denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 4 carbon atoms, chosen, for example, from : " the following values: ethenyl or vinyl, propenyl or R allyl, l-propenyl, n-butenyl, i-butenyl, 3-methyl-2- butenyl, n-pentenyl, hexenyl, heptenyl, ‘octenyl, cyclohexylbutenyl and decenyl, and also the linear or branched positional isomerers thereof. :
Among the alkenyl values that may be mentioned particularly are the values allyl or butenyl. ws - the term “alkynyl radical” denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 4 carbon atoms, chosen, for example, from the following values: ethynyl, propynyl or propargyl, butynvyl, n-butynyl, i-butynyl, 3-methyl-2-butynyl, pentynyl or hexynyl, and also the linear or branched positional isomers thereof.
Among the alkynyl values that are mentioned more particularly is the propargyl value. - the term “alkoxy radical” denotes a linear or branched radical containing not more than 12 carbon atoms and preferably 6 carbon atoms chosen, for example, from methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, pentoxy, hexoxy and heptoxy radicals, and also the linear or branched positional isomers thereof,
® 25 . - the term “alkoxycarbonyl radical” or alkyl-0-CO- : denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above: examples that may be mentioned include methoxycarbonyl and ethoxycarbonyl radicals, - the term “alkylenedioxy radical” or -0O-alkylene-O- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkylene radical has the meaning given above: examples that may be mentioned include methylenedioxy and ethylenedioxy radicals, - the term “alkylsulfinyl” or alkyl-SO- denotes a linear or branched radical containing not more than 12 : carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms, - the term “alkylsulfonyl” or alkyl-S02- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the : meaning given above and preferably contains 4 carbon atoms, : - the term “alkylsulfonylcarbamoyl” or alkyl-SO2-NH-
C(=0)- denotes a linear or branched radical containing not more than 12 carbon atoms, in which the alkyl radical has the meaning given above and preferably contains 4 carbon atoms, - the term “alkylthio” or alkyl-S- denotes a linear. or branched radical containing not more than 12 carbon atoms and especially represents methylthio, ethylthio, isopropylthio and heptylthio radicals, - the term “cycloalkyl radical” denotes a 3- to 10- membered monocyclic or bicyclic carbocyclic radical and especially denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals, - the term “-O-cycloalkyl radical” denotes a radical in which the cycloalkyl radical has the meaning given above,
Claims (1)
- CLAIMS 1) A product of formula (I): Ri : y NT Y, N A p | R : 0 I | oo Y, - in which p represents an integer from 0 to 2, R and R1l, which may be identical or different, represent O or NH, R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3- to 10-: membered and the heterocyclic radical containing one or more hetero atoms chosen from O, 8S, N and NR7, all these radicals optionally being substituted,Al represents a single bond, an alkyl radical or an alkenyl or alkynyl radical, Y and Yl, which may be identical or different, are such that one from among Y and Y1 is chosen from OCF3, -O-CF2- CHF2, -0-CHF2, -0-CH2-CF3, SO2NR5R6, SF5 and ~-S(0O)n-alkyl and the other from among Y and Y1 is chosen from these same values and in addition from the following values: hydrogen, halogen, hydroxyl, alkoxy, nitro, CN, NRS5Reé, optionally substituted alkyl, optionally substituted aryl o 486 and heteroaryl, .CF3, O-alkenyl, O-alkynyl, O-cycloalkyl, S(O)n-alkenyl, S(O)n-alkynyl, S(O)n-cycloalkyl, free, salified or esterified carboxyl and CONRSR6, or alternatively the phenyl radical forms with its substituents Y and Y1 the following radicals:CF.2P . 0 —O with p representing the integer 2, 3 or 4, the radical : thus formed being optionally substituted with one or more alkyl radicals that are themselves optionally substituted, R5 and R6, which may ‘be identical or different, are chosen from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which are . optionally substituted, or alternatively R5 and Ré form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from O, S, N and NR7, which is optionally substituted, A2, which may be identical to or different from Al, represents the values of Al and CO and SO2, B2 represents a saturated or unsaturated monocyclic or bicyclic heterocyclic radical containing 1 or more identical or different hetero atoms chosen from 0, S, N and NR7, optionally substituted with one or more identical or different substitutents chosen from the values of Y2, R7 represents a hydrogen atom or an alkyl, cycloalkyl, phenyl, acyl, S(0)2Alk, S(0)2Aryl, S(O)2heteroaryl or S(O) 2NR5R6 radical, Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, cyclecalkyl, heterocycloalkyl, aryl, heteroaryl,® 487 O-alkenyl, O-alkynyl, O-cycloalkyl, S(0)n-alkyl, S(0)n- alkenyl, S(O)n-alkynyl, S(O)n-cycloalkyl, COOR13, OCOR13, NRS5R6, CONRSR6, S(0O)n-R5R6, -NR10-CO-R13, -NR10O-S02-R13, : NH-SO2-NRE5R6, -NR10-CO-NRS5R6, -NR10-C5-NR5R6, | _NR10- COOR13, all these radicals optionally being substituted, all the alkyl, alkenyl, alkynyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl and heterocycloalkyl radicals above containing not more than 7 carbon atoms, all the aryl and hetercaryl radicals above containing not more than 10 carbon atoms, all the carbocyclic and heterocyclic alkyl, alkenyl, ~ alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl radicals above and also the ring formed by R5 and R6 with the atom to which they are attached, optionally being substituted with one or more radicals, : which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, aryl, heteroaryl, -C(=0) -0RS9, -C(=0) -R8, -NR11R12, -C({=0) - we NR11R12, -N(R10)-C(=0) -R8, -N (R10) -C(=0) -ORS9, N (R10) - C(=0)-NR11R12, -N (R10) -S(0O)n-RS8, -S(0)n-R8, -N (R10) - S{(0)n-NR11R12 or -S(0)n-NR11lR1l2 radicals, all the aryl and heteroaryl radicals above furthermore being optionally substituted with one or more radicals chosen from alkyl, alkoxy and alkylenedioxy radicals, all the above cyclic radicals, and also the ring formed by R5 and Ré with the atom to which they are attached, being moreover optionally substituted with one or more radicals chosen from oxo and thioxo, n represents an integer from 0 to 2, R8 represents alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, hetercaryl and hetercarylalkyl, R9 represents the values of R8 and hydrogen, R10 represents hydrogen or alkyl,® 488 R11 and R12, .which may be identical or different, represent hydrogen, C3-C6 cycloalkyl, C1-C4 alkyl and phenyl, optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively R11 and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from0, S, N and NR7 and preferably a cyclic amine,R13, which may be identical to or different than R5 or R6, being chosen from the values of R5 or Re,: it being understood that the product of formula (I) is as defined below from a) to 4d):a) when p represents the integer 0, R represents oxygen, R1 represents oxygen, al represents a single bond or alkyl, Y and Y1, which may be identical or different, are : such that at least one represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl,b) when p represents the integer 0, R and R1l represent oxygen, Al represents a single bond or alkyl, Y and Y1,which may be identical or different, are such that at least one represents OCF3, SOAlk, S(0O)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk always substituted with a hydroxamate -CO-NHOH c¢) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that at least one represents S(O)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-® 489 : : membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, : d) when p represents an integer from 0 to 2, R and R1 represent oxygen, Al represents a single bond, Y and Y1, which may be identical or different, are such that one represents SO2Alk or SO2NH2 and the other represents NRSR6, A2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, + and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). : 2) The product of formula (I) as claimed in claim 1, in which p represents an integer from 0 to 2, ‘ R and R1l, which may be identical or different, represent O or NH,a R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3- to 10- membered and the heterocyclic radical containing one or more hetero atoms chosen from O, S, N and NR7, all these radicals optionally being substituted, Al represents a single bond, an alkyl radical or an allyl or propynyl radical, Y and Y1, which may be identical or different, are such that one from among Y and Y1 is chosen from OCF3, S(OYnCF3, S(0)nAlk, SO2CHF2, SO2CF2CF3 and SO0O2NR5R€é and the other from among Y and Yl is chosen from these same values and in addition from the following values:® 490 hydrogen, halogen, hydroxyl, alkoxy, NRSR6, optionally substituted alkyl, optionally substituted aryl and heteroaryl, CFs, O-allyl, O-propynyl, O-cycloalkyl, S(O)n-allyl, S(O)n-propynyl, S(0)n-cycloalkyl, free, salified or esterified carboxyl and CONRSRE,in which R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, alkenyl, cycloalkyl,cycloalkenyl, heterocycloalkyl, aryl and heteroaryl,which are optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from O, S, N: and NR7, which is optionally substituted,A2, which may be identical to or different from Al, represents the values of Al and CO and S02,B2 represents a saturated or unsaturated heterocyclic radical containing 1 or more identical or different :hetero atoms chosen from ©O, S and NR7, optionally substituted with one or more identical or different substitutents chosen from the values of Y2,R7 represents a hydrogen atom or an alkyl, cycloalkyl,phenyl, aryl, S(0)2alk, S(0)2aryl, S(O)hetercaryl andS(O) 2NR5R6 radical,Y2 represents hydrogen, halogen, hydroxyl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, O-allyl,O-propynyl, O-cycloalkyl, S(O)n-alkyl, S(0O)n-allyl,S(O)n-propynyl, S(O)n-cycloalkyl, COORS, OCORS, NRSR6,CONRERS6, S(O)n-R5R6, NHCORS, NH-S (0) NR8 or NH-S(0O)nCF3 orNH-SO2-NR5R6, all these radicals being optionally substituted,all the alkyl, alkenyl, alkynyl and alkoxy radicals above being linear or branched and containing not more than6 carbon atoms,all the cycloalkyl and heterocycloalkyl radicals above containing not more than 7 carbon atoms,all the aryl and heteroaryl radicals above containing not® | 491 : more than 10 carbon atoms, all the carbocyclic and heterocyclic alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and : heteroaryl radicals above optionally being substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, aryl, heteroaryl, -C(=0) -0R9, -C(=0) -R8, -NR11iR12, -C({=0) -NR11R12, -N{R10) -C(=0) -R8, -N (R10) -C(=0)-0CR9, N(R10)-C(=0) -NR11R12, -N(R10)-S(0O)n- R8, -5(C)n-R8, -N(R10) -S(0)n-NR11R12 or -S(0O)n-NR11R1l2 radicals, all the aryl and heteroaryl radicals above furthermore being optionally substituted with ‘one or more radicals chosen from alkyl and alkylenedioxy radicals, - n represents an integer from 0 to 2, R8 represents alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, : aryl, arylalkyl, heteroaryl and heterocarylalkyl, : R9 represents the values of R8 and hydrogen, R10 represents hydrogen or alkyl, wr R11 and R12, which may be identical or different, represent hydrogen, C3-C6 cycloalkyl, C€1-C4 alkyl and phenyl, optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl, alkoxy, CF3, nitro, phenyl and free, salified, esterified or amidated carboxyl radicals, or alternatively R11 and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from O, 8, N and NR7 and preferably a cyclic amine, it being understood that the product of formula (I) is as defined below from a) to 4d): a) when p represents the integer 0, R represents oxygen, R1 represents oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are® 492 . such that at least one represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that at least one represents OCF3, SOAlk, S(0)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain : optionally interrupted with oO, 8 or Nalk always substituted with a hydroxamate -CO-NHOH ¢c) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, ¥Y and Y1, which may be identical or different, are such that at least one represents S(O)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6- membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Y1, which may be. identical or different, are such that one. represents SO02Alk or SO2NH2 and the other represents NRGSR6, A2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said product of formula (I) being in any possible racemic, enantiomeric or diastereocisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I).® | 493 : 3) The product of formula (I) as claimed in claim 1 or 2, in which p represents an integer from 0 to 2, R and R1l, which may be identical or different, represent O or NH, R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, cycloalkyl, phenyl and heteroaryl, which are optionally substituted, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3- to 10- membered and the heterocyclic radical containing one or more hetero atoms chosen from O, S, N and NR7, all these radicals being optionally substituted, Al represents a single bond, an alkyl radical or an allyl : or propynyl radical, Y and Y1, which may be identical or different, are such that one from among Y and Y1 is chosen from OCF3, S(0)nCF3, S(0)nAlk, SO2CHF2, SO2CF2CF3 and SO2NR5R6 and ' the other from Y and Yl is chosen from the same values and in addition from the following values: hydrogen,i. halogen, hydroxyl, alkoxy, NR5R6, optionally substituted alkyl and phenyl, and optionally substituted pyrazolyl and pyridyl, in which R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, phenyl and hetercaryl, which are optionally substituted, or alternatively R5 and Ré form, with the nitrogen atom to which they are attached, a 3- to 10-membered heterocyclic radical containing one or more hetero atoms chosen from O, S, N and NR7, which is optionally substituted, A2, which may be identical to or different from Al, represents the values of Al and CO and SO2, B2 represents a saturated or unsaturated heterocyclic radical containing one or more hetero atoms, which may be identical or different, chosen from O, S, N and NR7,® 494 optionally substituted with one or more substituents, : which may be identical or different, chosen from the values of Y2,R7 represents a hydrogen atom or an alkyl, cycloalkyl or phenyl radical,Y2 represents hydrogen, halogen, hydroxyl, alkyl, alkoxy,cycloalkyl, heterocycloalkyl, phenyl, heteroaryl,O-cycloalkyl, S(O0)n-alk, S(O)n-cycloalkyl, COOR9, OCORS,NR5R6, CONRSR6, S(0O)n-R5R6, NHCOR8 and NH-S(O)nR8, all these radicals being optionally substituted,all the alkyl, alkenyl, alkynyl and alkoxy radicals above being linear or branched and containing not more than 6: carbon atoms,all the cycloalkyl and heterocycloalkyl radicals above containing not more than 7 carbon atoms,all the aryl and heteroaryl radicals above containing not more than 10 carbon atoms, :all the carbocyclic and heterocyclic alkyl, alkenyl,alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl radicals above being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cyano, hydroxyl,alkoxy, CF3, nitro, phenyl, heteroaryl, -C(=0) -0R9,-C(=0) -RS8, -NR11R12, -C{(=0) -NR11R12, -N(R10)-C(=0) -RS8, -N (R10) -C(=0)--0OR9, N (R10) -C(=0)-NR11R12, -N(R10)-S(0O)n-R8, -S{0)n-R8, -N(R10)-S(O)n-NR11R12 and -S{O)n-NR11lR1l2 radicals,all the aryl and heteroaryl radicals above also being optionally substituted with one or more radicals chosen from alkyl and alkylenedioxy radicals,n represents an integer from 0 to 2,R8 represents alkyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heterocycloalkylalkyl, phenyl or phenylalkyl, R9 represents the values of R8 and hydrogen,R10 represents hydrogen or alkyl,® 495 ’ R11 and R12, which may be identical or different, represent hydrogen, C1-C4 alkyl and phenyl, which are optionally : substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and hydroxyl, alkoxy, CF3, nitro, phenyl and free,. salified, esterified or amidated carboxyl radicals; or alternatively R11] and R12 form, with the nitrogen atom to which they are attached, a 5- to 7-membered cyclic radical containing one or more hetero atoms chosen from 0, S, N and NR7 and preferably a cyclic amine, it being understood that the products of formula (I) are as defined below from a) to d): a) when p represents the integer 0, R represents oxygen, R1 represents oxygen, Al represents a single bond or alkyl, Y and Y1l, which may be identical or different, are such that at least one represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other we imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, ¥Y and Y1, which may be identical or different, are such that at least one represents OCF3, SOAlk, S(0)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk always substituted with a hydroxamate -CO-NHCH c) when p represents the integer 0, R and R1l represent oxygen, Al represents a single bond or alkyl, Y and Yi, which may be identical or different, are such that at least one represents S(O)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or ¢- membered aromatic heterocyclic radical, then R2 and R3® 496 . are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl,d) when p represents an integer from 0 to 2, R and Rl represent oxygen, Al represents a single bond, Y and Yl, which may be identical or different, are such that one represents SO2Alk or SO2NH2 and the other represents NRSR6, A2 represents a single bond or alkylene and B2 represents an optionally substituted 5- to 10-membered heterocyclic radical, then R2 and R3 do not both represent hydrogen, said product of formula (I) being in any possible racemic, enantiomeric or diastereoiscmeric isomer form, : and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). 4) The product of formula (I) as defined in any one of the claims, in which Y and Yl, which may be identical or different, are such that one from among Y and Yl is chosen from OCF3, -O-CF2-CHF2, -0-CRF2, ~-O-CH2-CF3, S(0)nCF3, -S-CF2-CF2-CF3, -S(O)n-Alk, -S-Alk-O-Alk, -S- Alk-OH, -$-Alk-CN, -S-Alk-heterocycloalkyl, (description : morpholino, pyrrolidinyl, piperazinyl, optionally substituted with alk), -SO2CHF2, -SO2CF2CF3, -S0O2NR5R6 and -SFS5, in which Alk represents an alkyl. radical containing from 1 to 4 carbon atoms, and the other from among Y and Y1 is chosen from the following values: hydrogen, halogen, nitro, NRS5R6, free or esterified carboxyl, and CONRS5R6, or alternatively the phenyl radical forms, with its substituents Y and Y1, one of the following radicals: CF, J ;® 497 : : the radical thus formed being optionally substituted with one or more alkyl radicals, which are themselves optionally substituted, _ the other substituents of said products of formula (I) being chosen from the values defined in claim 1, it being understood that: a) when p represents the integer 0, R represents oxygen, R1 represents oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents OCF3 or Salk, A2 represents a single bond or alkyl and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that one : represents hydrogen and the other represents OCF3, SOAlk, ' S(0)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 we and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk always substituted with a hydroxamate -CO-NHOH c¢) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that one represents hydrogen and the other represents S(0)nAlk, A2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said product of formula (I) being in any possible racemic, enantiomeric or diastereocisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I).° 498 5) The product of formula (I) as defined in any one of the claims, in which one from among Y and Yl represents a hydrogen atom and the other is chosen from OCF3, S(0)nCF3, S(0)nAlk, SO2CHF2, SO2CF2CF3 and SO2NRS5R6,the other substituents of said product of formula (I) being chosen from the values defined in claim 1 and it being understood that:a) when p represents the integer 0, R represents oxygen, Rl represents oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that one represents hydrogen and the other represents OCF3 or Salk, A2 represents a single bond or : alkyl and B2 represents "an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other imidazolylalkyl, b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Yl, : which may be identical or different, are such that one represents hydrogen and the other represents OCF3, SOAlk, S(0O)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk always substituted with a hydroxamate -CO-NHOH«¢) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that one represents hydrogen and the other represents S(0)nAlk, a2 represents a single bond and B2 represents an optionally substituted 5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form,and also the addition salts with mineral and organic acids or with mineral and organic bases of said product hd 499 of formula (I). 6) The product of formula (I) as defined in any one of the claims, in which one from among Y and Yl represents a hydrogen atom and the other is chosen from S (0) nCF3, . 5 SOAlk, S{0O)2Alk, SO2CHF2, SO2CF2CF3 and SO2NRSR6, : the other substituents of said product of formula (I) being chosen from the values defined in claim. 1 and it being understood that the product of formula (I) is as defined below in a) and b): a) when p represents the integer 0, R and R1l represent oxygen, Al represents a single bond or alkyl, Y and Yl, which may be identical or different, are such that one represents hydrogen and the other represents SOAlk, S(0)2alk or SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk : always substituted with a hydroxamate -CO-NHOH b) when p represents the integer 0, R and Rl represent oxygen, Al represents a single bond or alkyl, Y and Y1, wr which may be identical or different, are such that one represents hydrogen and the other represents SOAlk or S(0)2Alk, A2 represents a single bond and B2 represents an optionally substituted ©5- or 6-membered aromatic heterocyclic radical, then R2 and R3 are not chosen from hydrogen, alkyl, arylalkyl, aryl and heteroaryl, said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). 7) The product of formula (I) as defined in any one of the claims, in which one from among Y and Y1 represents a hydrogen atom and the other 1s chosen from S(0)nCF3, SO2CHF2, SO2CF2CF3 and SO2NR5R6, the other substituents of said product of formula (I)o 500 being chosen from the values defined in claim 1 and it being understood that when p represents the integer 0, R and R1 represent oxygen, Al represents a single bond or alkyl, Y and Y1, which may be identical or different, are such that one represents hydrogen and the other represents SO2NH2, A2 represents CH2 and B2 represents an optionally substituted heterocyclic radical, then R2 and R3 do not represent one hydrogen and the other an alkyl chain optionally interrupted with O, S or Nalk, always substituted with a hydroxamate -CO-NHOH said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form,and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). 8) The product of formula (I) as defined in any one of the claims, in which one from among Y and Yl represents a hydrogen atom and the other is chosen from S(0)nCF3, SO2CHF2 and SO2CF2CF3, :the other substituents of said product of formula (I) being chosen from the values defined in claim 1, said product of formula (I) being in any possible racemic, enantiomeric or diastereocisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product. of formula (I).9) The product of formula (I) as defined in any one of the claims, such that all the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl radicals defined in claim 1 are optionally substituted with one or more radicals, which may be identical or different, chosen from halogen, cyano, hydroxyl, alkoxy, CF3, nitro, phenyl, carboxyl which is free, salified, esterified with an alkyl radical or amidated with a radical NRllaRl2a,-C(=0) -R9a, -NRllaRl2a, -C(=0)-NRllaRl2a, -N(Rl0a)-C(=0)- R9a, -N(R10a) -C(=0) -OR8a, N(R1l0a)-C(=0)-NR1laR1l2a, -® 501 : N(R10a)-S(0)n-R9a, -S(0)n-R9a, -N(R10a)-S(O)n-NRllaRl2a ~ or -(0)n-NRllaRl2a, all the aryl and heteroaryl radicals above furthermore being optionally substituted with an ethylenedioXy: 5 radical, :R8a represents hydrogen, alkyl, alkenyl, phenyl,phenylalkyl, heteroaryl or heterocarylalkyl, : :R9%a represents alkyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heterocycloalkylalkyl, phenyl, phenylalkyl, heteroaryl or heteroarylalkyl,R10a represents hydrogen or alkyl,Rlla and R12a, which may be identical or different represent hydrogen, alkyl, cycloalkyl, «cycloalkylalkyl, phenyl,phenylalkyl, optionally substituted with one or more substituents, which may be identical or different, chosen from halogen, hydroxyl, Cl-C4 alkyl or Cl-C4 alkoxy, or: alternatively Rlla and Rl2a form, with the nitrogen atom ' to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl,we indolinyl, pyrindolinyl, tetrahydroquinolyl, thiazolidinyl and naphthyridyl, said product of formula (I) being in any possible racemic, enantiomeric or diasterecisomeric isomer form,and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). 10) The product of formula (I) as defined in any one of the claims, such that p represents the integer 0, the other substituents of said product of formula (I) having the values defined in any one of the claims.11) The product of formula (I) as defined in any one of the claims, such that p represents the integer 1, the other substituents of said product of formula (I) having the values defined in any one of the claims.12) The product of formula (I) as defined in any one of® 502 the claims, such that p represents the integer 2, the other substituents of said product of formula (I) having the values defined in any one of the preceding claims.13) The product of formula (I) as defined in any one of the claims, such that R1 represents 0, the other substituents of said product of formula (I) having the values defined in any one of the claims. 14) The product of formula (I) as defined in any one of the claims, such that R represents 0, the other substituents of said product of formula (I) having the values defined in any one of the claims. 15) The product of formula (I) as defined in any one of : the claims, such that R2 and R3, which may be identical or different, represent hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, phenyl, phenylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heterocarylalkyl, which are optionally substituted, or : alternatively R2 and R3 form, together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, these radicals being 3- to 10- membered and the heterocyclic radical containing one or more hetero atoms chosen from O, S, N and NR7b, all these radicals being optionally substituted, all the above radicals being optionally substituted with 2% one or more radicals chosen from halogen, cyano, hydroxyl, alkyl and alkoxy containing 1 to 4 carbon atoms, CF3, nitro, phenyl, carboxyl which is free, salified, esterified with an alkyl radical or amidated with a radical NR11bR12b, -C(=0)-RSb, -NR11bR1l2b and -C(=0) -NR11bR12b, R7b represents a hydrogen atom, an alkyl radical or a phenyl radical, RS represents hydrogen, alkyl, cycloalkyl, cycloalkyl- alkyl or phenyl, R1lb and R12b, which may be identical or different, represent® 503 : hydrogen, alkyl, cycloalkyl or phenyl, or alternatively " R11b and R12b form, with the nitrogen atom to which they are attached, an optionally substituted piperazinyl radical, the other substituents of said product of formula (I) having the values defined in any one of the claims. 16) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl,phenylalkyl, pyridylalkyl, benzothienylalkyl and thienylbenzothienylalkyl, which are optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkyl and alkoxy radicals containing from one to 4 carbon atoms, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a 3- to 6 -membered cycloalkyl - or heterocycloalkyl radical containing a nitrogen atom, the: other substituents of said products of formula (I) having the values defined in any one of the claims.17) The product of formula (I) as defined in any one of wee the claims, such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl, hydroxyalkyl, phenylalkyl, hydroxyphenylalkyl, pyridylalkyl, benzothienylalkyl or thienylbenzothienylalkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms or an azetidinyl, pyrrolidyl or piperidyl radical,the other substituents of said products of formula (I) having the values defined in any one of the claims.18) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, are chosen from hydrogen, alkyl,hydroxyalkyl, phenylalkyl and hydroxyphenylalkyl, or alternatively R2 and R3 form, together with the carbon® 504 atom to which they are attached, a cycloalkyl radical : containing from 3 to 6 carbon atoms.19) The product of formula (I) as defined in any one of the claims, such that one from among R2 and R3 is chosen from hydrogen and alkyl, and the other from among R2 and R3 1s chosen from all the values of R2 and R3, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms,the other substituents of said product of formula (I) having the values defined in any one of the claims.20) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, represent hydrogen and alkyl, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cycloalkyl radical containing from 3 to 6 carbon atoms, the other substituents of said product of formula (I) having the values defined in any one of the claims.21) The product of formula (I) as defined in any one of the claims, such that R2 and R3, which may be identical or different, represent hydrogen and CH3, or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cyclopropyl radical,the other substituents of said product of formula (I) having the values defined in any one of the claims.22) The product of formula (I) as defined in any one of the claims, such that Al represents a single bond and A2 is chosen from a single bond, a linear or branched alkyl radical containing not more than 6 carbon atoms and allyl, ©propynyl, <C=0 and S02 radicals, the other substituents of said product of formula (I) having the values defined in any one of the claims.23) The product of formula (I) as defined in any one of the preceding claims, such that Al represents a single bond and A2 is chosen from a single bond, alkyl, allyl,® | 505 , propynyl, C=0 and S02 radicals, the other substituents of said product of formula (I) having the values defined in any one of the claims. : 24) The product of formula (I) as defined in any one of the claims, such that Al represents a single bond and A2 represents un alkyl or C=0 radical, the other substituents of said product of formula (I) having the values defined in any one of the claims. 25) The product of formula (I) as defined in any one of the claims, such that Al represents a single bond and A2 represents C=0, -CH2-CH2- or -CH2, the other substituents of said product of formula (I) having the values defined in any one of the claims. 26) The product of formula (I) as defined in any one of ~ the claims, such that Al represents a single bond and A2 represents -CH2, the other substituents of said preduct of formula (I) having the values defined in any one of the claims. : 27) The product of formula (I) as defined in any one of the claims, in which Y and Y1 are such that one i. represents a hydrogen atom, a halogen atom or an amino radical and the other is chosen from OCF3, -0O-CF2-CHF2, -O-CHF2, -0-CH2-CF3, -SF5, -S(0)n-CF3, -S (0)n-Aalk, -SO2CHF2, SO2CF2CF3, -SO2NH2, -S-CF2-CF2-CF3, -S-Alk-0O- Alk, -S-Alk-0OH, -S-Alk-CN, -8-Alk-morpholino, -S-Alk- pyrrolidinyl and -S-Alk-piperazinyl, the morpholino, pyrrolidinyl and piperazinyl radicals being optionally substituted with Alk, in which Alk represents an alkyl radical containing from 1 to 4 carbon atoms, the other substituents of said product of formula (I) having the values defined in any one of the claims. 28) The product of formula (I) as defined in any one of the claims, such that Y represents a hydrogen atom and vi is chosen from -0OCF3, S{(O)n-CF3, S(0O)n-CH3, SO2CHF2 and S02-N{(alk)2, the other substituents of said product of formula (I)® 506 having the values defined in any one of the claims. 29) The product of formula (I) as defined in any one of the claims, such that Y represents a hydrogen atom and Y1 is chosen from -OCF3, S{0O)n-CF3 and SO2CHF2,the other substituents of said product of formula (I)having the values defined in any one of the claims. 30) The product of formula (I) as defined in any one of the claims, such that Y represents a hydrogen atom and Y1 is chosen from -OCF3 and S(0O)n-CF3,the other substituents of said product of formula (I) having the values defined in any one of the claims.31) The product of formula (I) as defined in any one of : the claims, such that Y represents a hydrogen atom and Y1 is chosen from -OCF3, S-CF3 and S(0)2-CF3,the other substituents of said product of formula (I) having the values defined in any one of the claims.32) The product of formula (I) as defined in any one of the claims, such that B2 represents a monocyclic or bicyclic heteroaryl radical chosen from pyridyl, pyrimidinyl, quinolyl, azaindolyl, 1H- pyrrolo[2,3-blpyridinyl, guinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl, isoxazolyl, morpholinyl, pyrrolidinyl, furyl, piperidyl, thienyl, chromenyl, oxochromenyl, indolyl, pyrrolyl, purinyl,Dbenzoxazinyl, benzimidazolyl and benzofuranyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said product of formula (I) having the values defined in any one of the claims.33) The product of formula (I) as defined in any one of the claims, such that B2 represents a heteroaryl radical chosen from 3- or 4-pyridyl, pyrimidinyl, 3- or 4-guinolyl, azaindolyl, gquinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl and isoxazolyl radicals,these radicals being optionally substituted with one or more radicals chosen from the values of Y2,® | 507 : the other substituents of said product of formula (I) ~ having the values defined in any one of the claims. 34) The product of formula (I) as defined in any one of oo the claims, such that B2 represents a heteroaryl radical chosen from 3- or 4-pyridyl, pyrimidinyl, 3- or 4-quinolyl, azaindolyl and gquinazolyl radicals, these radicals being optionally substituted with one or more radicals chosen from the values of Y2, the other substituents of said product of formula (I) having the values defined in any one of the claims. 35) The product of formula (I) as defined in any one of the «claims, such that B2 represents 4-pyridyl and 4-quinolyl and 1H-pyrrolo[2,3-blpyrid-3-yl radicals optionally substituted with one or more radicals chosen from the values of Y2 defined in any one of the claims, the other substituents of said product of formula (I) having the values defined in any one of the claims. : 36) The product of formula (I) as defined in any one of the claims, such that Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, COOH, COCAlk, wr CONRSR6, NRS5R6, -NR10-COOR6, -NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-SO2-Ré, all these radicals being optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, cycloalkyl, phenyl and 5- or 6-membered heteroaryl radicals containing 1 to 3 hetero atoms chosen from O, N and S, all these radicals being optionally substituted, or alternatively R5 and R6 form, with the nitrogen atom to which they are attached, an optionally substituted pyrrolidinyl, piperidyl, piperazinyl, morpholinyl or quinazolinyl radical, R10 represents hydrogen or alkyl, all the alkyl, alkoxy, cycloalkyl and phenyl radicals above, and also the ring formed by R5 and R6 with the atom to which they are attached, being optionally substituted with one or more radicals, which may be® 508 identical or different, chosen from halogen atoms and the following radicals: cyano; hydroxyl; alkyl; alkoxy; OCF3; CF3; S(0O)n-CF3; nitro; oxo; thioxo; O0OCOAlk; phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals; -0COAlk; NH2, NHAlk, N(Alk)2, N (alk) (phenylalkyl), N(Alk) (aminoalkyl), N (Alk) (alkylaminoalkyl) N(Alk) (dialkylaminoalkyl) ; carboxyl in free form or esterified with an alkyl radical,all the phenyl radicals above also being optionally substituted with an alkylenedioxy radical, all the alkyl radicals above also being optionally: substituted with one or more saturated or partially unsaturated 4- to 7-membered heterocyclic radicals containing at least one nitrogen atom N and also 0 to 2 other hetero atoms chosen from O, N and S, all the pyrrolidinyl and quinazolinyl radicals above also : being optionally substituted with oxo or thioxo, all the alkyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl radicals above containing not more than 7 carbon atoms, the other substituents of said product of formula (I) having the values defined in any one of the claims.37) The product of formula (I) as defined in any one of the claims, such that Y2 represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, CONRSR6, NRERS6, -NR10-COOH, _NR10-COOAlk, -NR10-CO-RS6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-SO2-R6,RS and R6, which may be identical or different, are chosen from hydrogen; alkyl; cycloalkyl; phenyl; pyrimidinyl; thienyl; pyridyl; quinolyl; thiazolyl optionally substituted with one or two halogen atoms; pyran optionally substituted with one or more OCOAlk;phenyl substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy, amino, alkylamino,® 509 : : dialkylamino radicals and carboxyl in free form or esterified with an alkyl radical; alkyl substituted with phenyl, which is itself optionally substituted with one or more radicals chosen from halogen atoms, alkyl, oo 5 alkoxy, amino, alkylamino, dialkylamino, carboxyl in free form or esterified with an alkyl radical; alkyl substituted with piperazinyl, which is itself optionally substituted with one or more radicals chosen from AlKk, Alk-OH and pyridyl; alkyl substituted with imidazolyl; alkyl substituted with one or more radicals chosen from NH2, NHAlk, N(Alk) 2, N (alk) (phenylalkyl), N(Alk) (aminocalkyl), N(Alk) (alkylaminoalkyl) and N(Alk) (dialkylaminoalkyl) ; alkyl © substituted with morpholinyl optionally substituted with one or two Alk; alkyl substituted with pyrrolidinyl; alkyl substituted with piperidyl, which is itself optionally substituted with one or two Alk; alkyl substituted with thiomorpholinyl; alkyl substituted with azetidinyl; alkyl substituted with azepanyl, which is optionally substituted with oxo, we or alternatively R5 and Ré form, with the nitrogen atom to which they are attached, a pyrrolidinyl; piperidyl; piperazinyl; morpholinyl; or gquinazolinyl radical, all these radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and alkyl, hydroxyl and alkoxy radicals, and phenyl radicals the latter of which is itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals, the pyrrolidinyl and quinazolinyl radicals also being optionally substituted with oxo or thioxo, the piperazinyl radical itself being optionally substituted with one or more radicals chosen from Alk, Alk-OH and pyridyl, R10 represents hydrogen or alkyl,hg 510 all the alkyl or Alk and alkoxy radicals above being : linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl radicals above containing not more than 7 carbon atoms, all the phenyl radicals also being optionally substituted with a radical chosen from CF3, -QCF3, nitro and alkylenedioxy, the other substituents of said product of formula (I)having the values defined in any one of the claims.38) The product of formula (I) as defined in any one of the claims, such that Y2 represents V1, halogen, : hydroxyl, _C(=NH)NH2, OV1, 0-CO-V1, COOVl1, COV1, CO-NV1V2, -NV1v2, -NH-CO-V1, -NH-CO0-V1, -NH-NH-CO-V1,-NV1-CO-NV1V2, -NV1-CO-NHV1, -NH-CO-NHV1, -NH-S0O2-NHV1 and -NH-S02-V1, in which V1 and V2, which may be identical or different, represent a hydrogen atom, an alkyl, cycloalkyl or phenyl radical or a heterocyclic radical such as pyridinyl,pyrazolyl, imidazolyl, dihydroimidazolyl, tetrazolyl, morpholinyl, piperazinyl, piperazinylalkyl, alkylpiperazinyl, phenylpiperazinyl, thienyle, furanyl, piperidyl, methylpiperidyl, pyridyl, pyrrolidyl and pyrrolidylalkyl,all the alkyl, phenyl and heterocyclic radicals being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkyl, alkoxy, CF3, NH2, NHalk, N(alk)2 radicals and a phenyl radical, itself optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl or alkoxy radicals, all the phenyl and heterocyclic radicals above furthermore being optionally substituted with one or more alkyl radicals,the phenyl radicals furthermore being optionally substituted with NRS5R6 in which R5 and R6 are as defined® 511 : in claim 1, the other substituents of said product of formula (I) having the values defined in any one of the claims. 39) The product of formula (I) as defined in any one of : 5 the claims, such that Y2 represents hydrogen, halogen, alkyl, cycloalkyl, hydroxyl, alkoxy, carboxyl. which is free or esterified with an alkyl or phenyl radical, NHZ, NHalk, N(alk)2 and phenyl, all the alkyl, alkoxy and phenyl radicals being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, CC1-C4 alkyl, C1-C4 alkoxy, CF3, NH2, NHalk and N(alk)2 radicals and a phenyl radical, which is itself optionally substituted with one or more substituents chosen from halogen atoms and : hydroxyl or alkoxy radicals, all the phenyl radicals furthermore being optionally substituted with one or more Cl1-C4 alkyl radicals and : optionally substituted with NRS5R6 in which R5 and R6é are as defined above, the other substituents of said product of formula (I) we having the values defined in any one of the claims. 40) The product of formula (I) as defined in any one of the claims, such that Y2 represents hydrogen, F, Cl, CH3, CH2CH3, OH, OCH3, ©NH2, ©NHAlk and phenyl optionally substituted with NR5R6 in which R5 and R6 are as defined in claim 1, the other substituents of said product of formula (I) having the values defined in any one of the claims. 41) The product of formula (I) as defined in any one of the claims, such that B2 represents 4-pyridyl and 4- guinolyl radicals substituted with one or more radicals chosen from F, Cl, OH and OCH3, the other substituents of said product of formula (I) having the values defined in any one of the claims. 42) The product of formula (I) as defined in any one of the claims, corresponding to formula (IC):® 512 0 LE N R,C PS Cc | | © 1 1c) B,C le in which YC and Y1C are such that one represents a hydrogen atom, a halogen atom or an amino radical and the other is chosen from -OCF3, -O-CF2-CHF2, -0O-CHF2, -O-CH2-: CF3, -SF5, -S(O)n-CF3, _s(0)n-Alk, -SO2CHF2, SO2CF2CF3, -SO2NH2, -S-CF2-CF2-CF3, -S-Alk-0-Alk, -S-Alk-OH, -S-Alk-CN, -S-Alk-morpholino, -S-Alk-pyrrolidyl and -S-Alk- piperazinyl, the morpholino, pyrrolidyl and piperazinyl radicals being optionally substituted with Alk, with Alk representing an alkyl radical containing from 1 to 4 carbon atoms,or alternatively the phenyl radical forms with its substituents YC and Y1C one of the two following radicals:5 ® ALK SALK SL with Alk representing an alkyl radical containing from 1 to 4 carbon atoms, R2C and R3C, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2C and R3C, which may be identical or different, represent hydrogen or optionally substituted alkyl or alternatively R2C and R3C form, together with® 513 the carbon atom to which they are attached, a C€3-C10 : cycloalkyl or heterocycloalkyl radical,A2C represents a single bond or CH2, B2C represents pyridyl, pyrimidyl, quinolyl, azaindolyl,quinazolyl, thiazolyl, imidazolyl, pyrazolyl, furazanyl,isoxazolyl, morpholinyl, pyrrolidyl, furyl, piperidyl, chromenyl, oxochromenyl, quinazolyl, thienyl, indolyl, pyrrolyl, purinyl, benzoxazinyl, benzimidazolyl or benzofuryl radicals, optionally substituted with one or more radicals chosen from the values of Y2A, Y2CA represents hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, phenyl, COOH, COOAlk, CONRS5R6, NRS5R6, : -NR10-COOH, -NR10-CCOAlk, _NR10-CO-R6, -NR10-CS-NR5R6, -NR10-CO-NR5R6 or -NR10-S0O2-R6, all these radicals being optionally substituted, R5 and R6, which may be identical or different, are chosen from hydrogen, alkyl, cycloalkyl, phenyl, pyrimidyl, thienyl, pyridyl, quinolyl, thiazolyl and pyran, all these radicals being optionally substituted,or alternatively R5 and Ré form, with the nitrogen atom to which they are attached, an optionally substituted pyrrolidyl, piperidyl, piperazinyl, morpholinyl or quinazolinyl radical, R10 represents hydrogen or alkyl,all the alkyl, alkoxy, cycloalkyl and phenyl radicals above, and also the ring formed by R5 and R6 with the atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and the following radicals: cyano; hydroxyl; alkyl; alkoxy; OCF3; CF3; S(0)n-CF3; nitro; oxo; thioxo; OCOAlk; phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms and alkyl and alkoxy radicals; -OCOAlk; NH2, NHAlk, N (Alk) 2, N(alk) (phenylalkyl),N{Alk) (aminoalkyl) N(Alk) (alkylaminocalkyl)® 514 : N(Alk) (dialkylaminoalkyl) ; carboxyl in free form or esterified with an alkyl radical, all the phenyl radicals above also being optionally : substituted with an alkylenedioxy radical, all the alkyl radicals above also being optionally substituted with one or more radicals chosen. from the following radicals: piperazinyl, itself optionally substituted with Alk, Alk-OH and pyridyl; imidazolyl: morpholinyl; pyrrolidyl; piperidyl, itself optionally substituted with one or two alk; azepanyl optionally substituted with oxo, all the pyrrolidyl and gquinazolinyl radicals above also being optionally substituted with oxo or thioxo, all the alkyl and alkoxy radicals above being linear or branched and containing not more than 6 carbon atoms, all the cycloalkyl radicals above containing not more than 7 carbon atoms, n represents an integer from 0 to 2, : J said products of formula (IC) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, es and also the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (IC). 43) The product of formula (I) as defined in any one of the claims, corresponding to formula (IA):[0] N RA A o 1 (1A) BA : I in which:® 515 Y1A represents -OCF3, S{O)n-CF3 and SO2CHF2, . B2a represents 4-quinolyl and 4-pyridyl radicals optionally substituted with one or more radicals chosen from the values of Y2Aa, Y2A has the meaning given in any one of the claims for Y2, R2A and R3A, which may be identical or different, represent hydrogen or optionally substituted alkyl, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-Cl0 cycloalkyl or heterocycloalkyl radical, all the alkyl and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, OCF3, S(0)n-CF3, CF3, NH2, NHAlk and N (alk) 2,n represents an integer fom 0 to 2,said product of formula (IA) being in any possible : racemic, enantiomeric or diasterecisomeric isomer form,and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IA).44) The product of formula (IA) as defined in the preceding claim, in which Y1A, B2a, R2A and R3A have the meanings given above and Y2A represents halogen, -OH,-alk, Oalk, + -Oacvyl, -NR5AR6GA, -CO2H, -C02alk, -CO- NRSAR6A, -S(0)n-CF3, -NH-S(O)n-CF3 or phenyl radicals, alk representing a linear or branched alkyl radical containing not more than 6 carbon atoms, all the alkyl, alkoxy and phenyl radicals being optionally substituted,RBA and R6A, which may be identical or different, represent hydrogen, alkyl, cycloalkyl or phenyl, the alkyl and phenyl radicals being optionally substituted, or alternatively RS5A and R6A form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl, piperazinyl, indolinyl, pyrindolinyl, tetrahydroquinolyl® 516 : and azetidinyl radicals, all the alkyl, alkoxy and phenyl radicals being optionally substituted with one or more radicals chosen : from halogen, OH, alk, Oalk, OCF3, S(0O)n-CF3, CF3, NH2, NHAlk and N(alk)2, n represents an integer from 0 to 2, said product of formula (IA) being in any. possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IA).45) The product of formula (I) as defined in any one of the claims, corresponding to formula (IA) in which: Y1A represents -OCF3, SCF3 or S(0)2-CF3, ~B2a represents a 4-quinolyl or 4-pyridyl radical optionally substituted with one or two radicals chosen from halogen, -OH, alk, -0Oalk, -CO2H, -CO2alk, -NRS5AR6A,: -CF3, -OCF3 and optionally substituted phenyl, ‘RSA and R6A, which may be identical or different,represent hydrogen, alkyl, cycloalkyl or phenyl, the mas alkyl and phenyl radicals being optionally substituted,or alternatively R5A and R6A form, with the nitrogen atom to which they are attached, a cyclic radical chosen from pyrrolidyl, piperidyl, piperazinyl, morpholinyl,piperazinyl and azetidinyl radicals, R2A and R3A, which may be identical or different,represent hydrogen or optionally substituted alkyl, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-C6 cycloalkyl or heterocycloalkyl radical, all the alkyl and phenyl radicals being optionally substituted with one or more radicals chosen from halogen, OH, alk, Oalk, OCF3, S(O)n-CF3, CF3, NH2, NHalk and N(alk) 2,said product of formula (IA) being in any possible, racemic, enantiomeric or diastereoisomeric isomer form,® 517 and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IA).46) The product of formula (I) as defined in any one of the claims, corresponding to formula (IA) in which: Y1A represents -OCF3, SCF3 or S(0)2-CF3, B2a represents a 4-quinolyl or 4-pyridyl radical optionally substituted with one or two radicals chosen from halogen, -OH, alk and -Oalk,R2A and R3A, which may be identical or different, represent hydrogen and linear or branched alkyl containing not more than 4 carbon atoms optionally: substituted with a hydroxyl radical, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a C3-Cé cycloalkyl radical, said product of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, : and also the addition salts with mineral and organic acids or with mineral and. organic bases of said product of formula (IA).47) The product of formula (I) as defined in any one of the claims, corresponding to formula (IA) in which Yila represents OCF3, SCF3 or S(0)2CF3 and R2A and R3A, which may be identical or different, represent hydrogen andCH3, or alternatively R2A and R3A form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents having the values given in any one of the claims,said product of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IA).48) The product of formula (I) as defined in any one of the claims, corresponding to formula (IB):ht 518 ' 0 ee a, ~~ N R2 A N Oo i" (1B) I" Y, © in which R2, R3, Al, ¥, Yl, A2, B2 and Y2 have the ~ meanings given in any one of the claims, said product of formula (IB) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, : and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IB). we 49) The product of formula (IB) as defined in the preceding claim, in which Y1 represents OCF3, SCF3 or S(O)2CF3 and R2 and R3, which may be identical or different, represent hydrogen and CH3 or, alternatively R2 and R3 form, together with the carbon atom to which they are attached, a cyclopropyl radical, the other substituents having values given in any one of the claims, said product of formula (IB) being in any possible racemic, enantiomeric or diastereocisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (IB). 50) The product of formula (I) as defined in any one of the claims, the names of which are below: - (8)-5-methyl-l-quinol-4-ylmethyl-3-(4-trifluoromethane-® : :sul fonylphenyl)imidazolidine-2,4-dione trifluorcacetate : - (8)-5-methyl-1-pyrid-4-ylmethyl-3-(4-trifluoromethane- sul fonylphenyl)imidazolidine-2,4-dione trifluorocacetate - (S) -5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethyl- sulfanylphenyl)imidazolidine-2,4-dione trifluorocacetate - 5,5-dimethyl-1-quinol-4-ylmethyl-3-(4-trifluoromethane- sul fonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-S5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethane- sul fonylphenyl)imidazolidine-2,4-dione trifluorocacetate- (R)-S5S-methyl-l-guinol-4-ylmethyl-3-(4-trifluoromethyl- sulfanylphenyl)imidazolidine-2,4-dione trifluorocacetate - (R)-5-methyl-1-pyrid-4-ylmethyl-3-(4-trifluoromethane-: sulfonylphenyl)imidazolidine-2,4-dione trifluorocacetate - (R)-5-methyl-1-(3-methylpyrid-4-ylmethyl)-3-(4-tri-fluoromethanesulfonylphenyl) imidazolidine-2,4-dione trifluorcacetate - (R)-4-methyl-3-gquinol-4-ylmethyl-5-thioxo-1-(4-tri- fluoromethylsulfanylphenyl)imidazolidin-2-one trifluorocacetate :- (R)-5-isopropyl-l1-quinol-4-ylmethyl-3-(4-trifluoro- methylsulfanylphenyl) imidazolidine-2,4-dione trifluorocacetate - (R)-5-isopropyl-1-quinol-4-ylmethyl-3-(4-trifluoro- methanesulfonylphenyl)imidazolidine-2, 4-dione trifluorocacetate - (R)-5-(4-hydroxy-benzyl)-1-quinol-4-ylmethyl-3-(4-tri- fluoromethanesul fonylphenyl) imidazolidine-2,4-dione trifluoroacetate - (R)-5- (4-hydroxy-benzyl)-1-pyrid-4-ylmethyl-3-(4-tri-fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate - (R)-5-(1-hydroxy-ethyl)-1-quinol-4-ylmethyl-3-(4-tri- fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate- 4-quinol-4-ylmethyl-6-(4-trifluoromethylsulfanyl- phenyl) -4,6-diazaspiro[2.4]heptane-5,7-dione hg 520 : : trifluorocacetate - 4-quinol-4-ylmethyl-6- (4-trifluoromethanesulfonyl- phenyl) -4,6-diazaspiro(2.4]heptane-5,7-dione trifluorocacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethylsulfanylphenyl)- 4,6-diazaspiro [2.4] heptane-5,7-dione trifluoroacetate - 4-pyrid-4-ylmethyl-6-(4-trifluoromethanesulfonyl-- phenyl) -4,6-diazaspiro(2.4]heptane-5,7-dione trifluorocacetate - (R)-1-(3-hydroxypyrid-4-ylmethyl)-5-methyl-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluoroacetate - 5,5-dimethyl-1-quinol-4-ylmethyl-3- (4-trifluoromethoxy- phenyl) imidazolidine-2,4-dione trifluorocacetate E - 5,5-dimethyl-l-quinol-4-ylmethyl-3-(4-trifluoromethyl- sulfanylphenyl)imidazolidine-2,4-dione trifluorocacetate - 5,5-dimethyl-1- (3-methylpyrid-4-ylmethyl)-3-(4-tri- : fluoromethoxyphenyl)imidazolidine-2,4-dione trifluorocacetate - 5,5-dimethyl-1-(3-methylpyrid-4-ylmethyl)-3-(4-tri- wn fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluorcacetate - 5,5-dimethyl-1- (3-methylpyrid-4-ylmethyl) -3-(4-tri- fluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluorocacetate - 1- (3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri- fluoromethoxyphenyl)imidazolidine-2,4-dione trifluorocacetate - 1- (3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidine-2,4-dione trifluorcacetate - 1- (3-hydroxypyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri- fluoromethanesulfonylphenyl) imidazolidine-2,4-dione trifluorocacetate - 4-quinol-4-ylmethyl-6-(4-trifluoromethoxyphenyl) -4,6- diazaspiro [2.4] heptane-5,7-dione trifluorocacetate® 521 - 4-(3-methylpyrid-4-ylmethyl)-6-(4-trifluoromethylsulf- : anylphenyl) -4,6-diazaspiro [2.4] heptane-5,7-dione trifluorcacetate - 4- (3-hydroxypyrid-4-ylmethyl)-6-(4-trifluoromethoxy-phenyl) -4,6-diazaspiro [2.4] heptane-5,7-dione trifluorocacetate, - 4- (3-hydroxypyrid-4-ylmethyl) -6- (4-trifluoromethylsulf- anylphenyl) -4,6-diazaspiro [2.4] heptane-5,7-dione trifluorocacetate- 4- (3-hydroxypyrid-4-ylmethyl) -6-(4-trifluoromethane- sulfonylphenyl)-4,6-diazaspiro [2.4] heptane-5, 7-dione trifluorocacetate, :: said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form,and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). : 51) The product of formula (I) as defined in any one of the claims, the names of which are given below:- {4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl- sulfanylphenyl)imidazolidin-1-ylmethyl]lpyrid-2-yl}cyclo- propanecarboxamide trifluoroacetate;- 5,5-dimethyl-1-[2- (pyrid-2-ylamino)pyrid-4-ylmeth- yl] -3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4-dione; compound with trifluoroacetic acid;- N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl- sulfanylphenyl)imidazolidin-1-ylmethyl] pyrid-2- y1}isobutyramide; compound with trifluoroacetic acid;- N-{4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethyl-sulfanylphenyl)imidazolidin-1l-ylmethyl]lpyrid-2- yl}propionamide; compound with trifluoroacetic acid;- 1-(2-aminopyrid-4-ylmethyl)-5,5-dimethyl-3-(4-tri- fluoromethylsulfanylphenyl)imidazolidine-2,4-dione hydrochloride;® | 522 : : - {4-(5,5-dimethyl-2,4-dioxo-3~ (4-trifluoromethyl- sulfanylphenyl)imidazolidin-1-ylmethyl] pyrid-2-yl}pyrid- ine-2-carboxamide trifluorocacetate; - N-{4-(5,5-dimethyl-2,4-dioxo-3- (4-trifluoyomethyl- sulfanylphenyl)imidazolidin-1-ylmethyllpyrid-2-yl}-3- piperid-1-ylpropionamide trifluoroacetate; :- N-{4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethyl- sulfanylphenyl)imidazolidin-1-ylmethyl]lpyrid-2-yl}-3-[4- (2-hydroxyethyl)piperazin-1-yl]propionamide trifluorocacetate; - N-{4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethyl- sulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}-3- morpholin-4-ylpropionamide trifluorocacetate;- N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl- ~ sulfanylphenyl)imidazolidin-1-ylmethyllpyrid-2-yl}-3- pyrrolidin-1l-ylpropionamide trifluoroacetate; :- N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-: sulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}-3-(4- ‘ methylpiperazin-1-yl)propionamide trifluoroacetate; - 1-{4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethyl- i sulfanylphenyl)imidazolidin-1-ylmethyl]lpyrid-2-yl}-3- phenylurea;- 1-[2-(6-ethylpyrid-2-ylamino)pyrid-4-ylmethyl] -5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol- idine-2,4-dione;- 5,5-dimethyl-1-([2-(4-methylpyrid-2-ylamino)pyrid- 4-ylmethyl]-3- (4-trifluoromethylsulfanylphenyl) imid- azolidine-2,4-dione;- 5,5-dimethyl-1-[2-(6-methylpyrid-2-ylamino) pyrid-4-ylmethyl]l-3-(4-trifluoromethylsulfanylphenyl) imi- dazolidine-2,4-dione;- 1-[2-(4,6-dimethylpyrid-2-ylamino)pyrid-4-ylmeth- yl] -5,5-dimethyl-3- (4-trifluoromethylsulfanylphenyl) - ‘ imidazolidine-~2,4-dione;® 523 . - 1-[2-(3,5-dichloropyrid-2-ylamino)pyrid-4-ylmeth- yl] -5,5-dimethyl-3- (4-trifluoromethylsulfanylphenyl) - imidazolidine-2,4-dione; - 5,5-dimethyl-1-[2- (pyrid-4-ylamino)pyrid-4-ylmeth- vyll-3-(4-triflucromethylsulfanylphenyl)imidazolidine-2,4- dione;- 5,5-dimethyl-1-[2-(pyrid-3-ylamino)pyrid-4-ylmeth- y1l]l-3-(4-trifluoromethylsulfanylphenyl)imidazolidine-2,4- dione;- N-{4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethyl- sulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}-3-(2- oxoazepan-1l-yl)propionamide;- 3-(benzylmethylamino) -N-{4-[5,5-dimethyl-2, 4-di- ox0-3-(4-trifluoromethylsulfanylphenyl)imidazolidin-1- ylmethyllpyrid-2-yl}propionamide;- 4,5-diacetoxy-6-acetoxymethyl-2-(3-{4-[5,5-dimeth- yl-2,4-dioxo-3-(4-trifluoromethylsulfanylphenyl) - : imidazolidin-1-ylmethyl]lpyrid-2-yl}thioureidoacetic acid;- 5,5-dimethyl-1-[2- (5-methylpyrid-2-ylamino)pyri-din-4-ylmethyl]-3-(4-trifluoromethylsulfanylphenyl)imid- azolidine-2,4-dione;- N-{4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethyl- sulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}-3,5- dimethoxybenzamide trifluoroacetate;- 5,5-dimethyl-1-[2- (pyrazin-2-ylamino)pyrid-4-yl-. methyl] -3-(4-trifluoromethylsulfanylphenyl)imidazolidine- 2,4-dione trifluorocacetate; - N-{4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethyl- sul fanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}-3-(3-methylpiperid-1-yl)propionamide trifluoroacetate;- N-{4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluocromethyl- sul fanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}-3- (3,5-dimethylpiperid-1-yl)propionamide trifluoroacetate;- N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl-sulfanylphenyl)imidazolidin-1-ylmethyl]pyrid-2-yl}-3- methoxybenzamide trifluorocacetate;® | . : - {4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethyl- sulfanylphenyl) imidazolidin-1-ylmethyl]lpyrid-2-yl}pyzr- azine-2-carboxamide trifluorocacetate; - {4-(5,5-dimethyl-2,4-dioxo-3-(4-trifluoxomethyl- sulfanylphenyl) imidazolidin-1-ylmethyllpyrid-2-yl}thio- phene-2-carboxamide trifluoroacetate; - N-{4-[5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethyl- sulfanylphenyl) imidazolidin-1-ylmethyl]pyrid-2-yl}-4- methylbenzamide; compound with trifluoroacetic acid; - 1-isoquinolin-5-yl-5,5-dimethyl-3-(4-trifluoro- methylsulfanylphenyl)imidazolidine-2,4-dione; - 3-(4-acetylpiperazin-1-yl)-N-{4-[5,5-dimethyl-2,4- dioxo-3- (4-trifluoromethylsulfanylphenyl)imidazolidin-1- © ylmethyllpyrid-2-yl}propionamide; ~ - 3-[4- (2-diethylaminoethyl)piperazin-1-yl] -N-{4- [5,5-dimethyl-2,4-dioxo-3- (4-trifluoromethylsulfanyl- phenyl) imidazolidin-1-ylmethyllpyrid-2-yl}propionamide; : - N-{4-[5,5-dimethyl-2,4-dioxo-3~(4-triflucromethyl- sulfanylphenyl)imidazolidin-1-ylmethyl)pyrid-2-yl}-3- (2,6-dimethylmorpholin-4-yl)propionamide;i. - N-{4-(5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl- sulfanylphenyl) imidazolidin-1-ylmethyl]l pyrid-2-yl}-3- (4- pyrrolidin-1-ylpiperid-1-yl)propionamide; - N-{4-[5,5-dimethyl-2,4-dioxo-3-(4-trifluoromethyl- sulfanylphenyl) imidazolidin-1-ylmethyl)pyrid-2-yl}-2-(4- pyrrolidin-1l-ylpiperid-1-yl)acetamide; - 5,5-dimethyl-1-[2- (4-methylpyrid-3-ylamino)pyrid- 4-ylmethyl] -3- (4-trifluoromethylsulfanylphenyl) imid- azolidine-2,4-dione; - 5,5-dimethyl-1-[2- (6-morpholin-4-ylpyrid-3-yl- amino) pyrid-4-ylmethyl}-3- (4-trifluoromethylsulfanyl- phenyl) imidazolidine-2,4-dione; . - 1-[2-(2,6-dimethylpyrid-3-ylamino)pyrid-4-ylmeth- y1l]-5,5-dimethyl-3- (4-trifluoromethylsulfanylphenyl)imid- azolidine-2,4-dione;hg 525 .- methyl. 5-{4-[5,5-dimethyl-2,4-dioxo-3- (4-tri- fluoromethylsulfanylphenyl)imidazolidin-1-ylmethyl]pyrid- 2-ylamino}pyridine-2-carboxylate; - 1-[2-(2,6-dimethoxypyrid-3-ylamino)pyrid-4-ylmeth- vyl]-5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imid- azolidine-2,4-dione; - 1-[2-(6-fluoropyrid-3-ylamino)pyrid-4-ylmethyl] - 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol- idine-2,4-dione;- 1-[2-(6-methoxypyrid-3-ylamino)pyrid-4-ylmethyl] - 5,5-dimethyl-3-(4-trifluoromethylsulfanylphenyl)imidazol- idine-2,4-dione,said products of formula (1) being in any possible racemic, enantiomeric or diastereoisomeric isomer form,and also the addition salts with mineral and organic acids or with mineral and organic bases of said product of formula (I). : 52) As a medicinal product, the product of formula (I) as defined in claims 1 to 51, and also the prodrugs thereof, the said product of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said product of formula (I). : 53) As a medicinal product, the product of formula (ICQ) as defined in the preceding claims, and also the prodrugs thereof, said product of formula (10) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said product of formula (IC).54) As a medicinal product, the product of formula (Ia)as defined in the preceding claims, and also the prodrugs thereof, the said product of formula (IA) being in any hg 526 : possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and. organic . 5 bases of said product of formula (IA). . 55) As a medicinal product, the product as defined in claim 50 or 51, and the prodrugs thereof,. and the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of these products. 56) A pharmaceutical composition containing, as active principle, at least one of the medicinal products as defined in claims 52 to 55. 57) A pharmaceutical composition containing, as active principle, at least one of the medicinal products as defined in claim 44. : 58) The pharmaceutical composition as defined in the claims, also «containing active principles of other chemotherapy medicinal products for combating cancer. 59) The pharmaceutical composition as claimed in any one wn of the claims, characterized in that it is used as a medicinal product, in particular for cancer chemotherapy. 60) The use of the product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I) for the preparation of medicinal products for inhibiting the activity of protein kinases and especially of a protein kinase. 61) The use of a product of formula (I) as defined in the preceding claim or of pharmaceutically acceptable salts of said product of formula (I) in which the protein kinase is a protein tyrosine kinase. 62) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I), in which the protein kinase is chosen from the following group: EGFR, Fak, FLK-1, FGFR1l, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R,he 527 KDR, PLK, PDGFR,. tie2, VEGFR, AKT, Raf. ‘ 63) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of the said product of formula (I) in which the protein kinase is IGF1R.64) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) in which the protein kinase is FAK.65) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) in which the protein kinase is AKT. 66) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) in which the protein kinase is in a cell culture.67) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) in which the protein kinase is in a mammal.68) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I), for the preparation of a medicinal product for preventing or treating a disease characterized by the deregulation of the activity of a protein kinase.69) The use of a product of formula (I) as claimed in the preceding claim, in which the disease to be prevented or treated is in a mammal.70) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I), for the preparation of a medicinal product for preventing or treating a disease belonging to the following group: disorders of blood vessel proliferation, fibrotic disorders, disorders: of mesangial cell proliferation, metabolic disorders, allergies, asthma, thrombosis, diseases. of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, : "diabetes, muscle degeneration, “oncology diseases and cancers. 71) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I), for the preparation of a medicinal product for treating oncology diseases. 72) The use of a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I) for the preparation of a medicinal product for treating cancers. oo © 73) The use of a product of formula (I) as claimed in the preceding claim, in which the disease to be treated is a cancer of solid tumors. : 74) The use of a product of formula (I) as claimed in : the preceding claim, in which the disease to be treated is a cancer that is resistant to cytotoxic agents. 75) The use of a product of formula (I) as defined in i. any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) for the preparation of a medicinal product for treating cancers including breast cancer, stomach cancer, cancer of the colon, lung cancer, cancer of the ovaries, cancer of the uterus, brain cancer, cancer of the kidney, cancer of the larynx, cancer of the lymphatic system, cancer of the thyroid, cancer of the urogenital tract, cancer of the tract including the seminal vesicle and prostate, bone cancer, cancer of the pancreas and melanomas. 76) The use of a product of formula (I) as claimed in the preceding claim, in which the disease to be treated is a breast cancer, cancer of the colon or lung cancer. 77) The use of a product of formula (I) as defined in any one of the claims, or of a pharmaceutically acceptable salt of said product of formula (I), for the, Y PCT/FR2004/000188 preparation of a medicinal product for cancer chemotherapy. 78) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I), for the preparation of a medicinal product for cancer chemotherapy, used alone or in combination. 79) The use of a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I) for the preparation of a medicinal product to be used alone or in combination with a chemotherapy or radiotherapy, or alternatively in combination with other therapeutic agents. 80) The use of a product of formula (I) as claimed in the preceding claim, in which the therapeutic agents may be commonly used antitumor agents. 81) The product of formula (I) as defined in any one of the claims, &s protein kinase inhibitor, said product of formula (I) being in any possible racemic, enantiomeric or diastereocisomeric isomer form, and also the addition salts with pharmaceutically acceptable mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said product of Iormula (I), and also prodrugs thereof. 82) The product of formula (I) as defined in any one of the claims, as an IGF1R inhibitor. 83) The product of formula (IA) as defined in the claims, as an IGF1IR inhibitor. 84) A substance or composition for use in a method for inhibiting the activity of protein kinases and especially of a protein kinase, said substance or composition comprising the product oi Iormula (1), as defined in any one cof the claims or of pharmaceutically acceptable salts AMENDED SHEET v PCT/FR2004/000188 of said product of formula (I), and said method comprising administering said substance or composition. 85) A substance or composition for use in a method ZIor preventing or treating a disease characterized by the deregulation of the activity of a protein kinase, said substance or composition comprising a product of formula (I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I), and said method comprising administering said substance or composition.86) 2A substance or composition for use in a method for preventing or treating a disease belonging to the following group: disorders of blood vessel proliferation, fibrotic disorders, disorders of mesangial cell proliferation, metabolic disorders, allergies, asthma, thrombosis, diseases of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, oncology diseases and cancers, said substance or composition comprising a product of formula(I) as defined in any one of the claims or of pharmaceutically acceptable salts of said product of formula (I), and said method comprising administering said substance or composition.87) A substance or composition for use in a method for treating oncclogy diseases, said substance or composition comprising a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I), and said method comprising administering said substance or composition.88) A substance or composition for use in a method for Treating cencers, sald substance or composition comprising a proauct of Zorrula (I) as defined in any one of the claims or of pharmaceutically acceptable salts ofAMENDED SrIET\| PCT/FR2004/000188 said product of formula (I), and said method comprising administering said substance or composition. 89) A substance or composition for use in a method for treating cancers including breast cancer, stomach cancer, cancer of the colon, lung cancer, cancer of the ovaries, cancer of the uterus, brain cancer, cancer of the kidney. cancer of the larynx, cancer of the lymphatic system, cancer of the thyroid, cancer of the urogenital tract, cancer of the tract including the seminal vesicle and prostate, bone cancer, cancer of the pancreas and melanomas, said substance or composition comprising a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I), and said method comprising administering said substance or composition. 90) A substance or composition for use in a method for cancer chemotherapy, said substance or composition comprising a product of formula (I) as defined in any one of the claims, or of a pharmaceutically acceptable salt of said product of formula (1), and said method comprising administering said substance or composition. 91) A substance or composition for use in a method for cancer chemotherapy, used alone or in combination, said substance or composition comprising a product of formula (I) as defined in any one of the claims or of a pharmaceutically acceptable salt of said product of formula (I), and said method comprising administering said substance or composition. 82) A substance or composition for use in a method to be used alone or in combination with a chemotherapy or radiotherapy, or alternatively in combination with other therapeutic agents, said substance or composition comprising a product of formula (I) as defined in any one AMENDED SHEET“ PCT/FR2004/000188 of the claims or of a pharmaceutically acceptable salt of said product of formula (I), and said method comprising administering said substance or composition. 93) A product of any one of claims 1 to 51 or 81 to 83, substantially as herein described and illustrated. 24) 2A medicinal product of any one of claims 52 to 595, substantially as herein described and illustrated. 95) A composition of any one of claims 56 to 59, substantially as herein described and illustrated.96) Use of any one of claims 60 to 80, substantially as herein described and illustrated.87) A substance or composition for use in a method of prevention or treatment of any one of claims 84 to 92, substantially as herein described and illustrated.98) A new product, a new medicinal product, a new composition, a new use of a product as claimed in any one of claims 1 to 51 or 81 to 83, or a substance or composition for a new use in a method oi treatment or prevention, substantially as herein described.AMZINDED SHERT
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0301098A FR2850652B1 (en) | 2003-01-31 | 2003-01-31 | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200505934B true ZA200505934B (en) | 2007-06-27 |
Family
ID=32696243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200505934A ZA200505934B (en) | 2003-01-31 | 2005-07-22 | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1599464B1 (en) |
JP (1) | JP4604020B2 (en) |
KR (1) | KR20050098286A (en) |
CN (1) | CN1768054A (en) |
AR (1) | AR042936A1 (en) |
AT (1) | ATE482207T1 (en) |
AU (1) | AU2004209319A1 (en) |
BR (1) | BRPI0407091A (en) |
CA (1) | CA2513631A1 (en) |
DE (1) | DE602004029236D1 (en) |
FR (1) | FR2850652B1 (en) |
HR (1) | HRP20050679A2 (en) |
MA (1) | MA27651A1 (en) |
ME (1) | MEP22608A (en) |
MX (1) | MXPA05007407A (en) |
NO (1) | NO20054006L (en) |
NZ (1) | NZ541270A (en) |
PE (1) | PE20040808A1 (en) |
PL (1) | PL377811A1 (en) |
RS (1) | RS20050657A (en) |
RU (1) | RU2341523C2 (en) |
TW (1) | TW200505898A (en) |
WO (1) | WO2004070050A2 (en) |
ZA (1) | ZA200505934B (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004315596B2 (en) | 2003-08-29 | 2011-11-24 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
ATE502298T1 (en) | 2003-12-19 | 2011-04-15 | Univ California | METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES |
US7718684B2 (en) | 2004-02-24 | 2010-05-18 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies and compounds |
EP1621535A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
FR2896504B1 (en) * | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
FR2896503B1 (en) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | NOVEL CYCLIC UREA SULFUR DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
ES2593379T3 (en) | 2006-03-27 | 2016-12-09 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and diseases associated with the androgen receptor |
JP5350217B2 (en) | 2006-03-29 | 2013-11-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Diarylthiohydantoin compounds |
EP2061767B1 (en) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
MX2009006228A (en) | 2006-12-12 | 2009-06-22 | Schering Corp | Aspartyl protease inhibitors. |
UY31432A1 (en) | 2007-10-26 | 2009-05-29 | DIARILHIDANTOINE COMPOUNDS | |
EP2381775A4 (en) | 2008-12-23 | 2012-08-15 | Harvard College | Small molecule inhibitors of necroptosis |
US9108944B2 (en) | 2010-02-16 | 2015-08-18 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
US8685256B2 (en) * | 2010-12-21 | 2014-04-01 | Cytec Technology Corp. | Microdispersions of hydroxamated polymers and methods of making and using them |
US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
CN104661658A (en) | 2012-09-26 | 2015-05-27 | 阿拉贡药品公司 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
JOP20200097A1 (en) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
GB201312492D0 (en) * | 2013-07-12 | 2013-08-28 | Syngenta Ltd | Herbicidal compounds |
US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
KR20160122736A (en) | 2014-01-14 | 2016-10-24 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Heteroaryls and uses thereof |
WO2016094846A1 (en) | 2014-12-11 | 2016-06-16 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
TWI726969B (en) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | Substituted thiohydantoin derivatives as androgen receptor antagonists |
CN107619388A (en) * | 2016-07-13 | 2018-01-23 | 南京天印健华医药科技有限公司 | Heterocyclic compound as FGFR inhibitor |
CN114014844B (en) * | 2016-07-20 | 2024-10-01 | 诺华股份有限公司 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors |
CN111479560A (en) | 2017-10-16 | 2020-07-31 | 阿拉贡药品公司 | Antiandrogen for treating non-metastatic castration-resistant prostate cancer |
JP7005779B2 (en) * | 2017-10-31 | 2022-02-10 | ペレメッド カンパニー リミテッド | Pharmaceutical composition for the prevention or treatment of acute myeloid leukemia or metastatic breast cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2329276A1 (en) * | 1975-10-29 | 1977-05-27 | Roussel Uclaf | NEW SUBSTITUTES IMIDAZOLIDINES, METHOD OF PREPARATION, APPLICATION AS A MEDICINAL PRODUCT AND COMPOSITIONS CONTAINING THEM |
DE4228717A1 (en) * | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidine derivatives |
DE19540027A1 (en) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituted imidazolidine-2,4-dione compounds as active pharmaceutical ingredients |
ATE233738T1 (en) * | 1997-03-03 | 2003-03-15 | Boehringer Ingelheim Pharma | SMALL MOLECULES APPLICABLE IN THE TREATMENT OF INFLAMMATORY DISEASES |
DE19732928C2 (en) * | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Use of substituted imidazolidine-2,4-dione compounds as pain relievers |
FR2796945B1 (en) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | NOVEL DERIVATIVES OF HYDANTOINS, THIOHYDANTOINS, PYRIMIDINEDIONES AND THIOXOPYRIMIDINONES, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS |
KR100527290B1 (en) * | 2000-05-31 | 2005-11-09 | 다나베 세이야꾸 가부시키가이샤 | INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
PL374162A1 (en) * | 2002-05-16 | 2005-10-03 | Bayer Cropscience Gmbh | Pyridine carboxamide derivatives and their use as pesticides |
-
2003
- 2003-01-31 FR FR0301098A patent/FR2850652B1/en not_active Expired - Fee Related
-
2004
- 2004-01-22 PE PE2004000090A patent/PE20040808A1/en not_active Application Discontinuation
- 2004-01-27 AR ARP040100233A patent/AR042936A1/en unknown
- 2004-01-28 AT AT04705838T patent/ATE482207T1/en not_active IP Right Cessation
- 2004-01-28 ME MEP-226/08A patent/MEP22608A/en unknown
- 2004-01-28 CN CNA2004800088356A patent/CN1768054A/en active Pending
- 2004-01-28 BR BR0407091-7A patent/BRPI0407091A/en not_active IP Right Cessation
- 2004-01-28 AU AU2004209319A patent/AU2004209319A1/en not_active Abandoned
- 2004-01-28 KR KR1020057014096A patent/KR20050098286A/en not_active Application Discontinuation
- 2004-01-28 NZ NZ541270A patent/NZ541270A/en unknown
- 2004-01-28 WO PCT/FR2004/000188 patent/WO2004070050A2/en active Application Filing
- 2004-01-28 RU RU2005127335/04A patent/RU2341523C2/en not_active IP Right Cessation
- 2004-01-28 DE DE602004029236T patent/DE602004029236D1/en not_active Expired - Lifetime
- 2004-01-28 EP EP04705838A patent/EP1599464B1/en not_active Expired - Lifetime
- 2004-01-28 MX MXPA05007407A patent/MXPA05007407A/en active IP Right Grant
- 2004-01-28 RS YUP-2005/0657A patent/RS20050657A/en unknown
- 2004-01-28 CA CA002513631A patent/CA2513631A1/en not_active Abandoned
- 2004-01-28 PL PL377811A patent/PL377811A1/en not_active Application Discontinuation
- 2004-01-28 JP JP2006502123A patent/JP4604020B2/en not_active Expired - Fee Related
- 2004-01-30 TW TW093102064A patent/TW200505898A/en unknown
-
2005
- 2005-07-22 ZA ZA200505934A patent/ZA200505934B/en unknown
- 2005-07-29 HR HR20050679A patent/HRP20050679A2/en not_active Application Discontinuation
- 2005-07-29 MA MA28417A patent/MA27651A1/en unknown
- 2005-08-29 NO NO20054006A patent/NO20054006L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1768054A (en) | 2006-05-03 |
NO20054006D0 (en) | 2005-08-29 |
FR2850652B1 (en) | 2008-05-30 |
RS20050657A (en) | 2007-06-04 |
PE20040808A1 (en) | 2004-12-31 |
PL377811A1 (en) | 2006-02-20 |
MEP22608A (en) | 2010-06-10 |
RU2005127335A (en) | 2006-09-10 |
DE602004029236D1 (en) | 2010-11-04 |
JP4604020B2 (en) | 2010-12-22 |
AU2004209319A1 (en) | 2004-08-19 |
TW200505898A (en) | 2005-02-16 |
KR20050098286A (en) | 2005-10-11 |
NZ541270A (en) | 2008-11-28 |
MXPA05007407A (en) | 2005-09-12 |
WO2004070050A3 (en) | 2005-02-17 |
CA2513631A1 (en) | 2004-08-19 |
EP1599464B1 (en) | 2010-09-22 |
ATE482207T1 (en) | 2010-10-15 |
MA27651A1 (en) | 2005-12-01 |
WO2004070050A2 (en) | 2004-08-19 |
AR042936A1 (en) | 2005-07-06 |
NO20054006L (en) | 2005-10-13 |
HRP20050679A2 (en) | 2006-12-31 |
BRPI0407091A (en) | 2006-01-24 |
EP1599464A2 (en) | 2005-11-30 |
RU2341523C2 (en) | 2008-12-20 |
JP2006517569A (en) | 2006-07-27 |
FR2850652A1 (en) | 2004-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200505934B (en) | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors | |
US20240139194A1 (en) | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | |
US7642278B2 (en) | Indazole benzimidazole compounds | |
US7064215B2 (en) | Indazole benzimidazole compounds | |
US7186716B2 (en) | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | |
KR101675984B1 (en) | Thienodiazepine derivatives or pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising the same as an active ingredient | |
BR112019008061A2 (en) | methods of using indazol-3-carboxamides and their use as inhibitors of the wnt / b-catenin signaling pathway | |
CN113646307B (en) | Pyrido [3,4-d ] pyrimidin-8-one derivatives having protein kinase inhibitory activity and pharmaceutical compositions thereof | |
WO2014004863A2 (en) | Compounds, compositions, and therapeutic uses thereof | |
EP3010503A2 (en) | Novel bicyclic bromodomain inhibitors | |
JP2001508800A (en) | Phthalazine having angiogenesis inhibitory activity | |
JP2016520116A (en) | Imidazopyrrolidinone derivatives and their use in the treatment of diseases | |
JP2015514802A (en) | Methods and compositions for RAF kinase mediated diseases | |
TW200303863A (en) | Substituted indazoles, compositions comprising them, manufacturing process and use | |
US11304929B2 (en) | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | |
JP2016537384A (en) | Pyrrolopyrrolone derivatives and their use as BET inhibitors | |
WO2016115869A1 (en) | Novel inhibitor of flt3 kinase and use thereof | |
JP7285249B2 (en) | Novel [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors | |
RU2780168C1 (en) | NEW DERIVATIVE OF PYRIDO [3,4-d] PYRIMIDINE-8-ONE WITH PROTEIN KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, CONTAINING ABOVE DERIVATIVE | |
TWI759829B (en) | Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors | |
US20240217968A1 (en) | Pharmaceutical compound | |
EP4377304A1 (en) | Srpk inhibitors | |
AU2010319382A1 (en) | Kinase inhibitors |